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Role of SMAD2 and SMAD3 on Adipose Tissue Development and Function
Abstract
Introduction: Obesity and its associated metabolic syndrome are major medical problems worldwide
including United States. Adipose tissue is the primary site of energy storage, playing important roles in
health. Adipose tissue also has other critical functions, producing adipocytokines and contributing to
normal nutrient metabolism, which in turn play important roles in satiety, inflammation, and total energy
homeostasis. Activin A and activin B play important roles in maintaining body composition and energy
homeostasis. This dissertation highlights the role of activin/SMADs signaling in adipose tissue
development, function, and maintenance.
SMAD2/3 proteins are downstream mediators of transforming growth factor-β (TGFβ) family signaling,
including activins, which regulate critical preadipocyte and mature adipocyte functions. Previous studies
have demonstrated that Smad2 global knockout mice exhibit embryonic lethality, whereas global loss of
Smad3 protects mice against diet-induced obesity and the direct contributions of Smad2 and Smad3 in
adipose tissues individually or in combination and the responses of these tissues to activin signaling are
unknown. Additionally, our lab demonstrated that the combined loss of activin A and activin B have
reduced adiposity in mice and appearance of brown-like cells in visceral white adipose tissue. However,
the cell-autonomous role of activins on cell proliferation and differentiation remained unknown in vitro.
My hypothesis was that activin signaling regulate adipocyte differentiation and functions via SMAD2/
3-mediated mechanism(s) and that the individual or combined adipose-specific deletion of SMAD2/
SMAD3 would result in reduced adiposity similar to activin deficient mice.
Objective: Here, we sought to determine the primary effects of adipocyte-selective reduction of Smad2 or
Smad3 individually and in combination, on diet-induced adiposity and to establish whether preadipocytes
isolated from subcutaneous and visceral white adipose tissues differ in their differentiation capacity. We
also assessed the role of activins on cell proliferation and differentiation using an in vitro model.
Research Design: To assess the adipose-selective requirements of Smad2, Smad3 and Smad2/3, we
generated three lines of adipose-selective conditional knockout (cKO) mice including Smad2cKO,
Smad3cKO, and Smad2/3 double cKO mice using Smad2 and/or Smad3 “floxed” mice intercrossed with
Adiponectin-Cre mice. Additionally, we isolated preadipocytes and examined adipogenic activity of
visceral and subcutaneous preadipocyte and the effects of activin on preadipocyte proliferation and
differentiation in vitro. Furthermore, we used mouse embryonic fibroblasts (MEFs) from wild type mice
and activin double knockout mice to study the cell autonomous role of activin on differentiation and cell
fate.
Results: Our results demonstrated that subcutaneous preadipocytes differentiate uniformly and almost all
wildtype subcutaneous preadipocytes differentiated into mature adipocytes. In contrast, visceral
preadipocytes differentiated poorly. Exogenous activin A promoted proliferation and suppressed
differentiation of subcutaneous preadipocytes more robustly given that visceral adipocytes differentiate
poorly at baseline. Additionally, global knockout of activin A and B promoted differentiation and browning
in differentiated MEFs in vitro consistent with in vivo studies. Furthermore, we showed that Smad2cKO
mice did not exhibit significant effects on weight gain, irrespective of diet, whereas Smad3cKO male mice
displayed a trend of reduced body weight on high fat diet. On both (LFD and HFD) diets, Smad3cKO male
mice displayed an adipose depot-selective phenotype, with significant reduction in subcutaneous fat
mass but not visceral fat mass. Smad2/3cKO male mice did not show any difference in body weight or fat
mass compared to control mice. Female mice with adipose-selective combined deletion of Smad2/3,
displayed reduced body weight and reduction of fat mass in both visceral and subcutaneous depot with
higher metabolic rate on HFD compared to control littermates.

Conclusions: Our study demonstrated that Smad3 is an important contributor to the development and/or
maintenance of subcutaneous white adipose tissue in a sex-selective fashion. Combined reduction of
Smad2/3 protects female mice from diet induced obesity and is important for visceral and subcutaneous
depots in a sex-selective fashion. These findings have implications for understanding SMAD-mediated,
depot selective regulation of adipocyte growth and differentiation. Activin treatment promoted
proliferation of preadipocytes, while activin deficiency promoted differentiation and altered the phenotypic
characteristics of White adipocytes to brown-like cells in vitro consistent with in vivo.
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Abstract

Roshan Kumari
Role of SMAD2 and SMAD3 on Adipose Tissue Development and
Function
Introduction: Obesity and its associated metabolic syndrome are major medical problems
worldwide including United States. Adipose tissue is the primary site of energy storage,
playing important roles in health. Adipose tissue also has other critical functions, producing
adipocytokines and contributing to normal nutrient metabolism, which in turn play important roles in satiety, inflammation, and total energy homeostasis. Activin A and activin
B play important roles in maintaining body composition and energy homeostasis. This
dissertation highlights the role of activin/SMADs signaling in adipose tissue development,
function, and maintenance.
SMAD2/3 proteins are downstream mediators of transforming growth factor-β (TGFβ) family signaling, including activins, which regulate critical preadipocyte and mature
adipocyte functions. Previous studies have demonstrated that Smad2 global knockout mice
exhibit embryonic lethality, whereas global loss of Smad3 protects mice against diet-induced
obesity and the direct contributions of Smad2 and Smad3 in adipose tissues individually
or in combination and the responses of these tissues to activin signaling are unknown.
Additionally, our lab demonstrated that the combined loss of activin A and activin B have
reduced adiposity in mice and appearance of brown-like cells in visceral white adipose
tissue. However, the cell-autonomous role of activins on cell proliferation and differentiation remained unknown in vitro. My hypothesis was that activin signaling regulate
adipocyte differentiation and functions via SMAD2/3-mediated mechanism(s) and that
the individual or combined adipose-specific deletion of SMAD2/SMAD3 would result in
reduced adiposity similar to activin deficient mice.
Objective: Here, we sought to determine the primary effects of adipocyte-selective reduction of Smad2 or Smad3 individually and in combination, on diet-induced adiposity and to
establish whether preadipocytes isolated from subcutaneous and visceral white adipose
tissues differ in their differentiation capacity. We also assessed the role of activins on cell
proliferation and differentiation using an in vitro model.
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Research Design: To assess the adipose-selective requirements of Smad2, Smad3 and
Smad2/3, we generated three lines of adipose-selective conditional knockout (cKO) mice
including Smad2cKO, Smad3cKO, and Smad2/3 double cKO mice using Smad2 and/or
Smad3 “floxed” mice intercrossed with Adiponectin-Cre mice. Additionally, we isolated
preadipocytes and examined adipogenic activity of visceral and subcutaneous preadipocyte
and the effects of activin on preadipocyte proliferation and differentiation in vitro. Furthermore, we used mouse embryonic fibroblasts (MEFs) from wild type mice and activin double
knockout mice to study the cell autonomous role of activin on differentiation and cell fate.
Results: Our results demonstrated that subcutaneous preadipocytes differentiate uniformly
and almost all wildtype subcutaneous preadipocytes differentiated into mature adipocytes.
In contrast, visceral preadipocytes differentiated poorly. Exogenous activin A promoted
proliferation and suppressed differentiation of subcutaneous preadipocytes more robustly
given that visceral adipocytes differentiate poorly at baseline. Additionally, global knockout
of activin A and B promoted differentiation and browning in differentiated MEFs in vitro
consistent with in vivo studies. Furthermore, we showed that Smad2cKO mice did not
exhibit significant effects on weight gain, irrespective of diet, whereas Smad3cKO male mice
displayed a trend of reduced body weight on high fat diet. On both (LFD and HFD) diets,
Smad3cKO male mice displayed an adipose depot-selective phenotype, with significant
reduction in subcutaneous fat mass but not visceral fat mass. Smad2/3cKO male mice did
not show any difference in body weight or fat mass compared to control mice. Female mice
with adipose-selective combined deletion of Smad2/3, displayed reduced body weight and
reduction of fat mass in both visceral and subcutaneous depot with higher metabolic rate
on HFD compared to control littermates.
Conclusions: Our study demonstrated that Smad3 is an important contributor to the development and/or maintenance of subcutaneous white adipose tissue in a sex-selective
fashion. Combined reduction of Smad2/3 protects female mice from diet induced obesity
and is important for visceral and subcutaneous depots in a sex-selective fashion. These
findings have implications for understanding SMAD-mediated, depot selective regulation of adipocyte growth and differentiation. Activin treatment promoted proliferation of
preadipocytes, while activin deficiency promoted differentiation and altered the phenotypic
characteristics of White adipocytes to brown-like cells in vitro consistent with in vivo.
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Chapter 1
Introduction

1.1

Obesity

Obesity is a health epidemic worldwide with tremendous impact on the global economy
and health care systems. According to National Health and Nutrition Examination Survey
(NHANES), the prevalence of obesity has doubled in the past decade and nearly a third
of the world’s population is now clinically obese. In the United States alone, current data
suggests that obesity rates have tripled in adults, and this is a major contributing cause of
death (Karagozian, Derdák, and Baffy, 2014; Hruby and F. B. Hu, 2015; Chooi, Ding, and
Magkos, 2019). The occurrence of obesity is also not uncommon in children and adolescents.
Currently, about 42.4% of U.S. adults and about 18.4% of children and adolescents are obese
in United States (Matta et al., 2018; Sanyaolu et al., 2019) and data from the CDC shows that
US spends 14% (327 billion) of total health care expenditures annually to treat obesity or
obesity-related metabolic disease.
Obesity occurs due to energy imbalance between calories taken in and calories burnt.
This imbalance can happen when there is an imbalance in dietary intake such as higher
intake of fatty food, due to sedentary lifestyle or genetic defects (Wright and Aronne, 2012).
Obesity is a complex disease associated with the development of an array of metabolic
diseases including insulin resistance, type 2 diabetes, hypertension, cardiovascular disease,
fatty liver disease, and certain types of cancer, collectively termed, the metabolic syndrome
(Grundy, 2004; Marchesini et al., 2008; DeFronzo, 2010). Obesity and associated metabolic
diseases remain a major problem and lack of effective treatment and the substantial morbidity associated with this illness. Although obesity research has a major impact in recent
decades and several anti-obesity medications have been developed, unwanted side effects,
including depression, anxiety and other psychiatric symptoms and more research is needed
to find effective ways to mitigate the adverse effects of currently available treatments. Therefore, the need is urgent for interventions that prevent the development of obesity or reduce
its severity while minimizing the side effects. Investigation of molecular mechanisms that
underly multifactorial metabolic abnormalities associated with obesity such as insulin
resistance and type 2 diabetes are of great importance.
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Obesity occurs due to an unhealthy increase in white adipose tissue (WAT) (P. Wang
et al., 2008; Jo et al., 2009). Adipose tissue plays a crucial role in maintaining energy
homeostasis. Unhealthy expansion of WAT dysregulates energy homeostasis by affecting
production of adipocytokines such as Leptin, Adiponectin and Resistin (Gardan, Gondret,
and Louveau, 2006; Rabe et al., 2008; Bederman et al., 2018). Dysregulation of adipocytokine
production and release impacts satiety and is a major determinant of obesity (Unger et al.,
2010). Adipose tissue dysfunction occurs with unhealthy enlargement of adipocytes termed,
adipocyte hypertrophy, and is associated with infiltration of macrophages within WAT,
inflammation and insulin resistance (J. M. Rutkowski, J. H. Stern, and P. E. Scherer, 2015;
Choe et al., 2016; Longo et al., 2019). Altered metabolism is in-part driven by changes in the
adipose tissue microenvironment (Choe et al., 2016). The enlargement of adipocytes and
enhanced adipogenesis participate in the progression to an obese phenotype and altered
metabolism (Choe et al., 2016; Longo et al., 2019).
Visceral and subcutaneous WAT depots are well-described for their important roles
in obesity and its co-morbidities (Gesta, Y. H. Tseng, and Kahn, 2007). Many researchers
agree that visceral WAT and subcutaneous WAT differ anatomically and have different physiological and metabolic functions. For example, visceral white adipose tissue is associated
with increased metabolic risk such as insulin resistance, type2 diabetes and inflammation
(Y.-W. Wang et al., 2017). In contrast, expansion in subcutaneous white adipose tissue
ameliorates insulin resistance and reduces the risk of type 2 diabetes (Mittal, 2019).
Transforming growth factor-β (TGF-β) and several other ligands in this family, including activin A and activin B, have direct effects on growth and development of a variety
of tissues, including adipose, thereby impacting energy homeostasis (C. W. Brown, HoustonHawkins, et al., 2000; Choy, Skillington, and Derynck, 2000; L. Li et al., 2009; C. K. Tan,
Leuenberger, et al., 2011; Yadav, Quijano, et al., 2011; Bonomi et al., 2012; M. J. Lee, 2018).
The functions of activin/SMADs signaling are also well studied in many tissues, including adipose (Kunihiro Tsuchida et al., 2009; Lonardo et al., 2011; Dani, 2013; Latres et al.,
2017; Song et al., 2017). Activins A and B have pleiotropic effects, including preadipocyte
proliferation, differentiation, and determining cell fate (C. W. Brown, L. Li, et al., 2003;
Hirai et al., 2005; Zaragosi et al., 2010; Zamani and Chester W. Brown, 2011; Namwanje
and C. W. Brown, 2016; Xue et al., 2016; Q. Zhu et al., 2018). Activins can signal via SMADmediated pathways and non-SMAD-mediated pathways (p38 MAPK, ERK, JNK). The focus
of this study was to investigate the role of activin-SMAD-mediated signaling pathways on
adipogenesis in vivo and in vitro.
In SMADs-mediated pathways, activins A and B signal through activin receptor type
II (activin receptor IIA (Act RIIA) or activin receptor IIB (Act RIIB) and activin receptors
type I (ALK4 and ALK7) and downstream transcriptional transducers, SMAD2 and SMAD3
(K. Tsuchida et al., 2004; Bernard, K. B. Lee, and Santos, 2006). The homo- or heterodimer of
SMAD2 and SMAD3 form a complex with the common SMAD, SMAD4. In preadipocytes,
SMAD2/SMAD3/SMAD4 regulate the transcription of downstream adipogenic genes with
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additional transcriptional cofactors (Darlington, Ross, and O. A. MacDougald, 1998; C. W.
Brown, L. Li, et al., 2003; Hirai et al., 2005; Fei et al., 2010; Zaragosi et al., 2010; Tsurutani
et al., 2011; Namwanje and C. W. Brown, 2016; Xue et al., 2016). During adipocyte differentiation, SMAD2/SMAD3 are phosphorylated, thereby inhibiting downstream transcriptional
regulators of adipogenesis, C/EBPα, C/EBPβ, C/EBPδ and PPARγ (Darlington, Ross, and
O. A. MacDougald, 1998; Choy, Skillington, and Derynck, 2000; Zaragosi et al., 2010; C. K.
Tan, Leuenberger, et al., 2011; C. K. Tan, Chong, et al., 2012). Activin A inhibits differentiation via SMAD2 signaling and promotes self-renewal of adipose progenitors by inducing
expression of Nanog (Q. Zhu et al., 2018). Although activin A inhibits differentiation in
3T3-L1 pre-adipocytes and in human adipose progenitors (Hirai et al., 2005; Zaragosi et al.,
2010; M. J. Lee, 2018), little is known about the role of activins on the differentiation of
mouse embryonic fibroblast cells (MEFs) and mouse preadipocytes.
SMAD2 and SMAD3, the downstream mediators of activin signaling, regulate many
biological processes during embryogenesis, as well as adipose tissue development, growth,
differentiation, and cell fate decisions (Nomura and E. Li, 1998; Weinstein et al., 1998; Datto
et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al., 2011; Yadav, Quijano,
et al., 2011). Although there is functional overlap, SMAD2 and SMAD3 also have distinct
functions such as the critical role of Smad2 during early gastrulation (Nomura and E. Li,
1998; Waldrip et al., 1998; Weinstein et al., 1998; Heyer et al., 1999; Ju et al., 2006; Kriseman
et al., 2019). In contrast, Smad3 global knockout mice are viable and fertile. However,
Smad3 knockout mice undergo postnatal growth retardation with immunodeficiencies,
predisposition of colorectal cancer and shortened lifespan (Y. Zhu et al., 1998; Ashcroft et al.,
1999; Datto et al., 1999; Yang et al., 1999; Q. Li, Pangas, et al., 2008; C. K. Tan, Leuenberger,
et al., 2011).

1.2

Scientific Premise

The roles of activin A, activin B and SMAD3 on body composition, adipocyte differentiation
and energy metabolism have been demonstrated using a variety of activin and Smad3 alleles
in vivo (C. W. Brown, L. Li, et al., 2003; C. W. Brown, Houston-Hawkins, et al., 2000;
L. Li et al., 2009; Tsurutani et al., 2011; Bonomi et al., 2012; Yadav, Quijano, et al., 2011;
C. K. Tan, E. H. Tan, et al., 2013). Global knockout of Smad3 results in reduced adiposity
and improved energy metabolism and protects mice from diet induced obesity (C. K. Tan,
Leuenberger, et al., 2011; Tsurutani et al., 2011; Yadav, Quijano, et al., 2011; Yadav and Rane,
2012; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al., 2011; Yadav, Quijano, et al., 2011;
C. K. Tan, Chong, et al., 2012; Yadav and Rane, 2012). However, these effects on adipose
could be due to contributions from other tissues such as skeletal muscle, liver and pancreas.
Despite the attempts to understand the role or activin/SMADs on adiposity, these studies
cannot exclude indirect, secondary influences from other metabolically active tissues such
as skeletal muscle, pancreas and liver, as shown by the tissue-selective effects of Smad3
deficiency on hepatic gluconeogenesis and pancreatic beta cell apoptosis (Yadav, Devalaraja,
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et al., 2017; J. H. Lee et al., 2020). Overall, the current literature suggests that inactivating
activin/SMAD signaling might have beneficial effects on metabolism (Fei et al., 2010; Xue
et al., 2016; Tao et al., 2019).
In contrast to Smad3, Smad2 null mice show embryonic lethality due to failures
in gastrulation and germ layer patterning (Nomura and E. Li, 1998; Waldrip et al., 1998;
Weinstein et al., 1998). Due to embryonic lethality in Smad2 global knockout mice, the
role of SMAD2 on adiposity has not been determined. Additionally, the adipose-selective
roles of SMAD3 individually and/or the combined adipose tissue-selective knockout of
Smad2 and Smad3 have not been assessed in this model. This opens a new platform to
address several key questions such as whether adipose selective reduction of Smad2 or
Smad3 (adipocyte specific conditional knockout, cKO) has any effect on adiposity and
protection from diet-induced obesity. Furthermore, the combinatorial effects of SMAD2
and SMAD3 have not been investigated to understand the selectivity of each SMAD2 and
SMAD3 protein and/or cooperation of both proteins in adipocytes. Similar to Smad3 global
knockout, whether adipose selective combined reduction of Smad2/3cKO shows beneficial
effects on adiposity and metabolism. This conditional double knockout mutant will also
inform whether SMAD2 and SMAD3 compensate, cooperate, or antagonize each other
in the context of activin signaling.
Our lab made the seminal discovery that activins A and B regulate adiposity and
that the combined loss of activin A and activin B reduce adiposity and has beneficial effects
on energy metabolism in vivo (C. W. Brown, L. Li, et al., 2003; L. Li et al., 2009). This also
transforms the phenotypic characteristics of white adipose tissue (WAT) to brown-like cells,
including multilocular smaller adipocyte, UCP1 positive adipocytes and other molecular
features and histologic features typically associated with brown adipose tissue (BAT). The
molecular mechanisms by which activins regulate energy homeostasis and browning is
not well understood. Although SMAD2/3 are the predominant downstream mediators of
activin signaling, whether SMAD2 and SMAD3 have overlapping and/or specific functions
in adipose tissues in response to activin signaling remains unknown. This leads to an
important area of investigation to address whether the adipose selective reduction of
SMAD2/3 (a) has beneficial effects on adiposity and (b) improves energy metabolism,
including glucose and lipid metabolism and total energy expenditure. Furthermore, in
continuation of our previous work in vivo, the role of activins in adipogenesis and cell
autonomous effects on cell fate in vitro remain unknown. Additionally, the role of activins
on the differentiation of preadipocytes derived from mouse adipose depots remains in
question.
Therefore, in my dissertation work, I aimed to investigate the direct effects of downstream mediators of activin signaling on adipose tissue development and function, specifically, adipose-selective effects of Smad2 and Smad3 deficiency individually and in combination of both (Smad2/3cKO) using adipose-specific conditional knockout (cKO) mice.
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Furthermore, I aimed to further characterize the role of activin A on preadipocyte proliferation and differentiation and to examine the difference between two distinct adipose depots
using preadipocytes isolated from visceral and subcutaneous WAT. Additionally, I aimed to
investigate the cell autonomous roles of activins A and B on adipogenesis and cell fate in
vitro, using mouse embryonic fibroblast cells (MEFs) isolated from activin A and activin B
global knockout mice.

1.3

Hypothesis and Objectives

The central hypothesis of my dissertation research was that activin signaling regulates
adipocyte differentiation and functions via SMAD2/3-mediated mechanism(s) and that the
individual or combined adipose-specific deficiency of SMAD2/SMAD3 would result in
reduced adiposity and beneficial changes in energy metabolism (Figure 1.1).

Figure 1.1: Hypothesis. Activin deficiency induces brown-like cells in WAT
and reduces adiposity. Activin signaling via SMAD2/3 may contribute to the
browning of WAT and reduce fat accumulation.

To test this hypothesis, this research project was comprised of two major studies; the
first study included analyses in vivo, and second involved in vitro assays. We tested the
hypothesis and achieved the goal of this research project in three specific aims.
Specific Aim 1: The primary objective of this study was to determine the effects of adipose
selective deficiency of Smad2, Smad3 and Smad2/3 on adiposity and determine if these
mice are resistant to diet-induced obesity. The histological and molecular characteristics associated with adipose selective SMAD2/3 deficiency were also examined.
Rationale: Previous studies have demonstrated that the global knockout of Smad3
in mice protects them from diet-induced obesity (DIO) and improves their overall
metabolic profile including glucose tolerance and insulin sensitivity. However, influences due to the global loss of the Smad3 could not be excluded and it is plausible that
SMAD3 deficiency in metabolically active organs such as skeletal muscle and liver
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might be contributing to the observed phenotype. Thus, dissecting the tissue specific
requirements and the molecular mechanisms by which Smad2 and Smad3 regulate
adiposity was the main aim. This study used a mouse model to better understand
the role of SMAD2 and SMAD3 on adiposity and DIO and associated molecular
mechanisms by which SMAD2/3 plays a crucial role during adipocyte development
and function.
To study the function of SMAD2 and SMAD3 signaling cascades in adipose tissue,
we had Smad2 f lox/ f lox , Smad3 f lox/ f lox and Adiponectin Cre (Adipoq-Cre) (Ju et al., 2006;
Q. Li, Pangas, et al., 2008; Eguchi et al., 2011) mice. Our institutional animal care
and use committee has approved all animal studies. I generated three independent
lines of adipose selective cKO mice including Smad2cKO (Smad2 f lox/ f lox ; Adiponectin
Cre), Smad3cKO (Smad3 f lox/ f lox ; Adiponectin Cre), and Smad2/3cKO (Smad2 f lox/ f lox ;
Smad3 f lox/ f lox ;Adiponectin Cre), to selectively inactivate Smad2, Smad3 and both Smad2/3
in adipose tissues (Y. Zhu et al., 1998; Ashcroft et al., 1999; Samaras et al., 2010) using
Smad2 and Smad3 “floxed” mice intercrossed with Adiponectin-Cre mice (Figure 1.2).

Figure 1.2: Breeding Strategy. Generation of Smad2, Smad3 (denoted as
“Smad”, left column) and Smad2/3 conditional knockout mice (right column).

These mice were fed a high fat diet (HFD) relative to low fat diet (LFD) and weights
were recorded weekly (time course) compared to control mice. These findings helped
us to determine whether the adipose selective reduction of Smad2, Smad3 and Smad2/3
have beneficial effects on adiposity. We compared previous findings from global
Smad3 knockout mice to the results of this study.
Specific Aim 2: My secondary objective was to determine the impact of individual and
combined Smad2/3 deletion on whole body metabolic activity and the metabolic consequences (overall metabolic profile) associated with the adipose-selective reduction
of SMAD2, SMAD3 and SMAD2/3.
Rationale: Adipose tissue dysfunction is associated with metabolic changes that occur
during obesity including glucose intolerance, insulin resistance, and altered energy
homeostasis. Increased fat accumulation, especially visceral fat, has been shown to
cause aberrant energy metabolism, leading to insulin resistance. Yadav et al., and
Tan et al., (Yadav, Quijano, et al., 2011; C. K. Tan, Leuenberger, et al., 2011) have
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shown that Smad3 global knockout mice have improved glucose tolerance and insulin
sensitivity. However, to date there have been no studies using Smad2, Smad3 or both in
an adipose selective manner, and additional investigation was needed to explore the
adipose selective functions of SMAD2 and SMAD3 in regulating energy homeostasis
with nutritionally challenged cKO mice and control mice. We explored the metabolic
consequences of Smad2/3 adipose selective deletion. Body fat composition was determined using Echo-MRI. Metabolic profiling was carried out using the Comprehensive
Laboratory Animal Monitoring System (CLAMS), glucose-tolerance testing (GTT)
and insulin tolerance testing (ITT) (Darrah et al., 2013; Bederman et al., 2018) (Figure
1.3).

Figure 1.3: Mouse Metabolic Phenotyping Flowchart.

Specific Aim 3: My third objective was to determine the roles of activin and SMADs on
cell proliferation, differentiation and energy metabolism using an in vitro model.
3A: My 1st subaim was to determine the cell autonomous effects of activin
A/SMAD3 on cell proliferation using preadipocytes.
Rationale: SMAD-mediated activin signaling is known to regulate cell proliferation.
Activin A promotes proliferation in 3T3-L1 and adipocyte progenitors (Hirai et al.,
2005; Zaragosi et al., 2010). Preadipocytes from visceral and subcutaneous depots
were isolated from mouse and proliferation rate was measured by treating them with
activin, activin receptor inhibitor, SB431542 and SMAD3 inhibitor, SIS3.
3B: My 2nd subaim was to determine the cell autonomous effects of activin and
SMAD3 on adipocyte differentiation and cell fate (browning) using mouse embryonic
fibroblast cells or preadipocytes.
Rationale: SMAD-mediated activin signaling is known to regulate adipocyte differentiation. Activin A inhibits differentiation via SMAD2 in 3T3-L1 and human adipocyte
progenitors (Hirai et al., 2005; Zaragosi et al., 2010). However, the cell autonomous
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roles of activins on cell differentiation and cell fate in primary culture cells had not
been assessed. In this aim, I performed in vitro experiments to understand the roles
of activins in adipocyte differentiation and cell fate using mouse embryo fibroblasts
(MEFs). Also, several research groups have reported conflicting results regarding the
effects of Smad3 on adipocyte differentiation. Yadav et al., (C. K. Tan, Leuenberger,
et al., 2011; Yadav, Quijano, et al., 2011) have shown that Smad3 promotes adipogenesis
while Tsurtani et al.,(Tsurutani et al., 2011) reported an inhibitory effect. In this study,
I examined the cell autonomous effects of Smad3 on preadipocyte differentiation.
Differentiated cells were also used to study browning phenomena (Figure 1.4).

Figure 1.4: Differentiation of Preadipocyte into Mature Adipocytes and
Associated Markers.

9

Chapter 2
Literature Review

2.1

An Overview of Obesity

Obesity and its associated metabolic syndrome are major medical problems worldwide.
Currently, the obesity rate has reached pandemic proportions rapidly increasing over the
past three decades. In the United States alone, the obesity rate exceeds 42% and is a
major risk factor for the development of several chronic diseases such as type 2 diabetes,
cardiovascular disease, fatty liver and certain types of cancer (Pi-Sunyer, 2009; Chooi, Ding,
and Magkos, 2019). Obesity is associated with increased risk of global morbidity and
mortality.
Obesity can be defined based on body mass index (BMI). Adults with BMI between
30-34.9 kg/m2 are classified as class I obese, BMI between 35-39.9 kg/m2, class II obese
and BMI ≥ 40 kg/m2 considered as severe or morbididly obese (Hruby and F. B. Hu, 2015).
In children, obesity is classified based on the percentile of BMI depending on the age and
sex, considering body composition as body composition differs between male and female
children as they grow. Children with BMI ≥ 95th percentile are considered obese while
BMI > 99th percentile is considered severely obese. Also, in the case of athletes and body
builders, an increase in BMI does not correlate with poor health status because of increase
in muscle mass and misleading BMI associated with weight (Whitlock et al., 2008; Weir and
Jan, 2021).

2.2

Cause and Consequences of Obesity

While some researchers think that obesity occurs due to social and environmental factors
such as diets with high fat content and sedentary lifestyle, others think that genetics plays a
predominant role. However, ample evidence in the literature supports a model in which obesity is caused by a combination of genes, nutrient environment, socioeconomic conditions
and behavior such as lifestyle choices (Allison et al., 2008). If one considers socioeconomic
factors that impact dietary choices, neighborhood food options and affordability are major
contributing factors, as food with higher fat content is more affordable than a nutritionally
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well-balanced diet. High caloric density intake and sedentary lifestyle, such as lack of
exercise, also contribute to obesity.

2.3

Cell Signaling Crosstalk and Obesity

Previous studies have shown that genetics contributes between to 40-70% to the development of obesity (Herrera and Lindgren, 2010). It can be monogenic or polygenic depending
on the individual’s obese condition and metabolic outcome. Monogenic obesity is rare
and involves single gene defects, most affecting satiety. Among these are Leptin (LEP) or
Leptin receptor (LEPR), Melanocortin 4 receptor (MC4R), Proopiomelanocortin (POMC), and
Prohormone convertase 1/3 (PCSK1). All have been shown to be sufficient to result in
obesity when functionally inactivated (Butler, 2016; Niazi et al., 2019). However, obesity
develops due to the combination of several gene-environment interactions, also influenced
by the microbiome diversity of an individual (Khera et al., 2019; Hüls et al., 2021). To study
polygenic obesity, different approaches have been taken to identify candidate genes, including single nucleotide polymorphisms (SNPs) identified through genome wide association
studies (GWAS), and by whole exome or whole genome sequencing of obese individuals.
GWAS have identified a total of 445 SNPs and 389 genes that are associated with obesity and
metabolism. These genes are involved in many different pathways associated with obesity
and related disorders (Cheng et al., 2018). These include key metabolic signaling pathways,
AMPK and PI3K-AKT, and genes that impact nutrient metabolism, including FTO, FOXO1,
FOXO3, CREB1, PPARγ and IRS1, most of which regulate gene expression as transcriptional co-regulators (Bernhard et al., 2013; Locke et al., 2015). These SNPs regulate disease
susceptibility by affecting the miRNA binding such as loci at the binding site of obesity
related transcription factors (CEBPs, CREB1),adipogenesis and lipid metabolism (PPARγ,
ADIPOQ, IRS1, TMEM18, FTO, SMAD7 etc.), and by affecting protein phosphorylation and
impacting expression of the adjacent gene (Q. Huang, 2015). The first obesity related gene
identified in GWAS is fat mass and obesity associated gene (FTO). The BMI-increasing allele
of FTO increases the risk of obesity by 1.2-fold, which is common in different age group
and diverse populations (Loos and Yeo, 2014; Merkestein et al., 2015).

2.4

Organs Contributing to Obesity

Obesity-related co-morbidities include insulin resistance, type 2 diabetes, fatty liver disease,
and dyslipidemia (Hruby and F. B. Hu, 2015; Chooi, Ding, and Magkos, 2019). Obesity
can cause problems with many organs including adipose tissue, liver, muscle, arteries,
brain, heart, lungs, immune system, pancreas, gallbladder, kidneys, breast, uterus, colon
and rectum (Giovannucci et al., 2010). Adipose tissue is the primary site of energy storage
and imbalance in energy intake and expenditure can lead to fat deposition in several other
organs, leading to insulin resistance and type 2 diabetes. Ectopic fat deposition in the liver
will lead to fatty liver disease (hepatic steatosis). Obese people are at high risk for stroke, as
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arteries in the brain can be narrowed by chronic fat deposition, termed, "atherosclerosis",
thereby blocking the blood supply to the brain. Arterial damage can also lead to heart
attack or peripheral vascular disease. Some risk factors such as insulin resistance and type 2
diabetes can be reversed by maintaining a healthier lifestyle, including increasing physical
activity and balanced diet.

2.5

Origin and Development of Adipose Tissue and Its Impact on
Adiposity

Adipose tissue is loose connective tissue that originates from the differentiation of mesenchymal stem cells (MSCs) into adipocytes during fetal development. Adipose tissue
consists of a heterogenous population of cell types such as preadipocytes, adipocytes, fibroblasts, endothelial cells, and various types of immune cells including macrophages, dendritic
cells, mast cells, B cells, T cells and neutrophils (Longo et al., 2019; Pyrina et al., 2020).
Adipose tissue (AT) is distributed throughout the body in several different depots and is
generally classified into two types, WAT and brown adipose tissue (BAT). Both arise from
different precursors, and each has distinct architecture, molecular function, mitochondrial
physiology and gene expression pattern. In addition to white and brown adipocytes, a third
type of adipocyte with “brown-like” characteristics, but inducible appearing in WAT has
been well described, termed “brite” or “beige” adipocytes.
The developmental origins of WAT, BAT and brite adipocytes have been rigorously
studied and are still controversial. Recent literature suggests that the origins of these
adipocytes are more complex than originally hypothesized. According to the literature,
mesenchymal stem cells can give rise to Myogenic factor 5- negative precursors (Myf5-)
which later assume the lineage of white adipocytes or brite adipocytes. Brite adipocytes
emerge in WAT under certain conditions and the emergence of the brown phenotype differs
from classical brown adipocytes that originate from Myogenic factor 5 positive (Myf5+)
precursors. Mf5+ positive precursors can give rise to classical brown adipocytes and
myocytes (Giralt and Villarroya, 2013). Brite adipocytes residing within WAT increase in
number after cold exposure, adrenergic stimulation, or administration of thiazolidinediones
(TZDs) such a rosiglitazone. These brite adipocytes arise either by differentiation of brite
preadipocytes or via trans-differentiation of white adipocytes. However, lineage tracing
studies suggest that preadipocytes not only arise from MSCs but also from additional cell
types such as vascular endothelial cells, neural crest cells and hematopoietic stem cells that
may contribute white and brown adipocyte lineage determination. However, the question
still remains as to whether this outcome is due to one cell type or many cell types within
WAT. Thus, many different cell types residing in WAT function together and maintain
overall whole body energy metabolism (Rosenwald and Wolfrum, 2014).
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White Adipose Tissue (WAT)

WAT is distributed throughout the body. White adipocytes are unilocular with a single,
large lipid droplet and fewer mitochondria than brown adipocytes. WAT is distributed in
several depots, which include visceral and subcutaneous WAT. Visceral fat is predominantly
found around internal organs such as the gonad, kidney, intestine, and pericardium while
subcutaneous fat is found beneath the skin. Both visceral and subcutaneous WAT differ
in terms of their structure, physiological roles, and molecular and metabolic functions.
Notably, dysfunction of visceral fat is associated with components of the metabolic syndrome such as type 2 diabetes and insulin resistance (Frayn, 2000). Subcutaneous WAT
serves as a protective cushion and insulates the body from extreme or low temperature .
However, the main function of WAT is to store excess energy as lipid, which is regulated
by several hormones including insulin, glucagon and catecholamines. Depending on the
energy demand, these hormones can work to store or break down triglycerides to release
fatty acids and glycerol. Accordingly, WAT regulates lipogenesis, lipolysis, the latter providing the substrate for fatty acid oxidation in the liver. WAT also serves as an endocrine
organ by secreting several adipokines such as leptin, adiponectin, resistin, estrogen and
cytokines such as TNF-alpha and several interleukins (IL6, ILB, IL10) by a variety of cell
types that reside in WAT. These factors regulate a variety of cellular functions in maintaining, satiety/food intake, inflammatory responses, energy substrate metabolism and
energy expenditure (Ahima and Lazar, 2008). Leptin and adiponectin have an influence on
glucose and lipid metabolism by regulating food intake and insulin sensitivity. Adiponectin
increases fatty acid oxidation and insulin sensitivity (B. Lee and J. Shao, 2012; Jennifer H.
Stern, Joseph M. Rutkowski, and Philipp E. Scherer, 2016).

2.7

Visceral and Subcutaneous WAT

Visceral and subcutaneous WATs differ morphologically, physiologically, and metabolically.
They differ in their structure, location, and metabolic function. Visceral fat disproportionately contributes to insulin resistance in obesity due to the accumulation of a variety of
immune cells and subsequent production of inflammatory cytokines (Frayn, 2000). The
increase in visceral fat mass through hypertrophy is metabolically harmful, increases
metabolic risk, overall mortality and can predispose to serious concerns such as type 2
diabetes, insulin resistance, dyslipidemia, heart disease, hypertension, and inflammation,
while increase in subcutaneous white adipose tissue through hyperplasia is associated with
a more “metabolically healthy” state of improved insulin sensitivity and lowers the risk
of type 2 diabetes (Fontana et al., 2007; Hajer, Haeften, and Visseren, 2008). However, it is
unclear that increase in fat mass or functional changes in fat tissue contribute to the development of insulin resistance in obese individuals. Although both visceral and subcutaneous
WAT express similar sets of genes, their expression levels differ, and when considering
differentially expressed genes, mostly lipogenic genes are expressed at higher levels in
visceral fat of obese individuals (Samaras et al., 2010; Ronquillo et al., 2019). Additionally,
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transplantation of subcutaneous fat into obese mouse visceral depots resulted in improved
metabolic characteristics, including decrease in body weight, and fat pads with improved
insulin sensitivity (Tran et al., 2008). Furthermore, the metabolic effect of increased fat mass
by transplantation of visceral fat from lean mice resulted in improved insulin sensitivity.
This suggests that irrespective of the amount or location of fat, normal metabolic performance of the visceral fat depot is critical to maintain normal metabolic function (Konrad,
Rudich, and Schoenle, 2007).
Visceral WAT has larger inflammatory cells than subcutaneous WAT and visceral
WAT undergoes lipolysis faster than subcutaneous WAT (Ibrahim, 2010). Additionally,
using adipocyte stem cells (ASC) researchers showed that the functional differences between visceral and subcutaneous depots start at the precursor level and remain in mature
adipocytes. The depots display distinct proliferation and differentiation rates with subcutaneous ASC having higher proliferation rate, adipogenic efficiency and membrane
potential than visceral. The depots start showing functional differences at very early stages
of development, so the differences are not restricted to mature adipocytes (Merrick, Sakers
et al. 2019). The differences in precursors may play a role in susceptibility to metabolic
disease. Further, subcutaneous ASC secrete more adiponectin and have reduced lipolytic
rate relative to visceral (Baglioni et al., 2012). Additional metabolic studies show that ASC
from both depots use both glycolysis and oxidative phosphorylation for energy production;
however, visceral ASC mostly use glycolysis. This suggest that the difference in adipogenic
potential is due to the difference in mitochondrial activity (Lefevre et al., 2019).

2.8

Brown Adipose Tissue (BAT)

BAT is a multilocular adipose tissue with densely packed mitochondria, enriched in the
suprascapular region of the upper neck and mostly found in infants. The main function of
BAT is to increase energy expenditure and generate heat by non-shivering thermogenesis.
BAT uses stored fat as its substrate upon cold exposure or adrenergic stimulation (Cannon
and Nedergaard, 2004). BAT uses uncoupling protein1 (UCP1), activated by long chain fatty
acids to uncouple the mitochondrial respiratory chain from ATP production by proton leak
in the inner mitochondrial membrane to generate heat and maintain reactive oxygen species
(ROS) production. This includes transcriptional activation of the genes encoding UCP1.
UCP1 is involved in the oxidation of metabolic substrates and helps maintain glucose and
lipid homeostasis (Stanford and Goodyear, 2013). Several transcription factors like PGC1α
and PRDM16 are characteristically expressed in brown adipocytes and play a major role in
mitochondrial biogenesis.

2.9

Brite Adipose Tissue

Birte adipocytes have multilocular morphology, express UCP1 and resemble brown-like
cells within WAT with characteristics, functions, and gene signatures of classical brown
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adipocytes. This phenotype can be induced upon cold exposure or β- adrenergic signaling
or TZD administration (Rosenwald and Wolfrum, 2014). However, transcriptome analysis
showed that brite adipocytes express some unique markers, Tmem26, Tbx1, Cd137 that
are not expressed in the classical brown adipocyte marker sets Zic1, Prdm16, Lhx8, Cox8b
etc (Waldén et al., 2012; Wu et al., 2012). Given the distinct function of white and brown
adipocytes, “white to brite adipocyte” conversion may be due to trans-differentiation
without going back to the undifferentiated state. The britening in WAT has been shown
to improve overall metabolic profile including reduced adiposity and improved glucose
homeostasis (Guerra et al., 1998; Golozoubova, Hohtola, et al., 2001; Golozoubova, Cannon,
and Nedergaard, 2006; L. Cao et al., 2011).

2.10

Roles of Mitochondria in Adipose Tissues and Metabolism

Mitochondria play an important role in the regulation of energy expenditure, ATP production and disposal of ROS by regulating fatty acid oxidation (FAO) and glucose homeostasis.
Normally, adipose tissues maintain the appropriate balance between energy release and
storage and maintain normal mitochondrial function. With obesity, excess caloric intake
such as HFD increases the mitochondrial substrate load to all tissues involved in nutrient
metabolism (adipose, liver, and skeletal muscle) leading to mitochondrial dysfunction.
This increases oxidative stress and the production of ROS which will ultimately cause cell
damage and inflammation (Y. Lin et al., 2005). ROS will reduce oxygen consumption and
block fatty acid oxidation resulting in lipid accumulation. Treatment of 3T3L1 adipocytes
with glucose or NEFAs increase ROS, reduces mitochondrial biogenesis and cause insulin
resistance (Gao et al., 2010).
Mitochondrial biogenesis and activity play an important role and can have different
effects on adipocyte lipid metabolism. Several mitochondrial enzymes play important roles
in lipid metabolism. In case of energy demand, WAT releases NEFA by lipolysis which is
utilized as a substrate for FAO in liver and skeletal muscle and improves insulin sensitivity.
However, in the case of nutrient excess for an extended period, WAT lipogenic enzymes
use energy substrate to store triglycerides, leading to NEFA accumulation, mitochondrial
dysfunction, and insulin resistance. BAT and muscle cells, shares a common precursor,
have high oxidative activity due to higher mitochondrial density with similar expression
profile of FAO enzymes and OXPHOS components. Yet each cell type has uniques markers
that define the cellular phenotypes, including UCP1, which is unique to BAT (Bournat and
C. W. Brown, 2010).

2.11

Adipocyte Hypertrophy and Hyperplasia

Obesity is not only an increase in adipose tissue mass, but this is a result of both fat accumulation and fat distribution. Increase in adipose tissue mass can be caused by enlarged
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adipocyte size known as hypertrophy or an increase in adipocyte number during adipogenesis termed as hyperplasia (Choe et al., 2016; Longo et al., 2019). With obesity, WAT may
expand in an unhealthy or healthy way. Unhealthy expansion of WAT through hypertrophy
can lead to obesity associated metabolic complications such as hypoxia and mechanincal
reduction of the blood supply in the tissue, increased ROS production and inflammation
with more recruitment of macrophages. This also results in altered adipokine secretion and
mitochondrial dysfunction, type2 diabetes, insulin resistance and non-alcoholic fatty liver
disease. Healthy WAT expansion is metabolically beneficial, achieved via recruitment of
new adipocytes from precursors by differentiation. Alteration in preadipocyte differentiation is associated with metabolic complications (Lynes and Y. H. Tseng, 2018; Longo et al.,
2019)

2.12

Adipose Tissue Macrophages (ATMs)

Macrophages and other immune cells including CD4+ and CD8+ T cells, dendritic cells
and neutrophils play a crucial role in maintaining adipose tissue function. Hypertrophic
adipose tissue is associated with inflammation in which the number and composition of
macrophages and other immune cells abnormally changes. From healthy state to obese state
transition, the macrophages population increase from 5% to 50% within WAT, membrane
potential weakens and surrounds dead adipocytes to make crown-like structures in both
mice and humans. These macrophages change the inflammatory feature from an antiinflammatory state (M2) in lean individuals to a proinflammatory (M1) state during obesity.
These macrophages also contribute to the development of insulin resistance in obesity
and activate transcriptional cascade involved in lipolysis (X. Xu et al., 2013; Boutens and
Stienstra, 2016).

2.13

An Overview of Activin Signaling

The TGF-β family is comprised of over 33 ligands including TGF-β, activins, nodal, bone
morphogenic proteins (BMPs) and growth differentiation factors (GDFs) (Poniatowski Ł
et al., 2015). These ligands are divided into two major groups: TGF-β-like ligands including
activins and BMP-like ligands. Activins initiate signaling through a combination of type I
and II transmembrane serine/threonine kinase receptors. Many signaling pathways use
cascades of cytoplasmic molecules as relay transducers. The binding of TGF-β family
ligands with receptors and activation of downstream SMADs depend on the receptor
with which they interact (Zi, Chapnick, and X. Liu, 2012). SMAD2 and SMAD3 are the
cytoplasmic downstream effector proteins of activin signaling (Fei et al., 2010; Tsurutani
et al., 2011; Zamani and Chester W. Brown, 2011; Yadav, Quijano, et al., 2011; L. Zhang
et al., 2015; Namwanje and C. W. Brown, 2016; Xue et al., 2016; Wankhade et al., 2018;
Q. Zhu et al., 2018; Aragon et al., 2019; D. Wang et al., 2020). Classically, activins signal
through activin receptors and downstream transcriptional transducers SMAD2 and SMAD3.

Chapter 2. Literature Review

16

This drives a variety of activin functions during embryonic development and in adult
tissues including fat cells, where activins regulate proliferation, adipocyte differentiation,
cell fate determination, the management of body fat composition and energy homeostasis
(Waldrip et al., 1998; Y. Zhu et al., 1998; Ashcroft et al., 1999; Datto et al., 1999; C. W. Brown,
L. Li, et al., 2003; Dunn et al., 2004; Hirai et al., 2005; Ju et al., 2006; Itman et al., 2009;
Fei et al., 2010; Zaragosi et al., 2010; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al.,
2011; Yadav, Quijano, et al., 2011; Fleming et al., 2013; C. K. Tan, E. H. Tan, et al., 2013;
Kashiwagi et al., 2015; L. Liu et al., 2016; Xue et al., 2016; Y. P. Zhu et al., 2017; Aragon et al.,
2019). Activin/SMAD signaling is in part regulated by changes in equilibrium between the
cytoplasm and the nucleus (Caroline S. Hill, 2016).
Activin A (βA) and activin B (βB) ligands associate with activin receptors type
IIA or type IIB (ActRIIA or ActRIIB) and activate them to phosphorylate and activate
type I activin receptors (ActRI) such as activin receptor like kinase (ALK4 and ALK7).
Activated ALK4/ALK7 then transduce signal by phosphorylating the C-terminal Ser-Ser-XSer (SSXS) motif of regulatory SMADs (R-SMADs) SMAD2 and/or SMAD3. SMAD proteins
undergo a continuous cycle of nucleocytoplasmic shuttling. C-terminal phosphorylation
of SMAD2/3 allow interaction with the common mediator SMAD (Co-SMAD), SAMD4
to form heteromeric complexes and then translocate into the nucleus. In the nucleus,
the heteromeric complexes bind to the regulatory elements of target genes and regulate
transcription by transcription factors, transcriptional co-activators, or co-repressors to
impact a verity of biological function during embryonic development and in adult tissues,
including cell proliferation, differentiation, and cell fate determination. BMPs binds to BMP
receptors and signal transduction occurs via SMAD1/5/8 (J. Massagué, 1998; Joan Massagué,
2000; Chang, C. W. Brown, and Matzuk, 2002; Morikawa, Derynck, and Miyazono, 2016;
Derynck and Budi, 2019; Olsen et al., 2020)(Figure 2.2). SMADs activity is also controlled by
other posttranslational modifications such as sumoylation, that affect protein stability and
transcriptional activity (K. Tsuchida et al., 2004). SMAD6 and SMAD7 (inhibitory SMAD)
disrupt the binding of R-SMADs with co-SMAD. TGF-β-like ligands including activin can
also mediate the signal via non-SMAD mediated pathways such as p38MAPK, ERK1/2 and
JNK depending on the tissue type (Engel et al., 1999; Hanafusa et al., 1999; Fu et al., 2003;
W. Cao et al., 2004; J. Hu et al., 2016).

2.14

Adipogenesis and Key Transcription Factors Regulating Adipogenesis

Adipogenesis is a multistep temporal process of differentiation of preadipocytes into mature
adipocytes that includes early clonal expansion of preadipocytes and committed differentiation(Ailhaud, Grimaldi et al. 1994). For example, differentiation of pluripotent embryonic
stem cells (ESCs) into adipocytes starts with cell fate commitment into multipotential mesenchymal progenitors (MSCs) such as C3H10T1/2 cells and MEFs. MSCs undergo cell fate
determination and commitment to the preadipocyte, osteoblast, chondroblast or myoblast
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lineage(Gregoire, Smas et al. 1998, Hausman, DiGirolamo et al. 2001, Tang, Otto et al.
2003, Ghaben and Scherer 2019). Under the appropriate adipogenic culture conditions,
committed preadipocytes (3T3-L1, 3T3-F422A or primary preadipocytes) undergo mitotic
clonal expansion in which growth-arrested preadipocytes undergo a single round of cell
division before beginning the process of differentiation into mature adipocytes (Tang, Otto,
and Lane, 2004). Pref and Wnt10b expression are high in proliferating preadipocytes and
inhibit adipogenesis by inhibiting the expression of Cebpβ and Cebpδ by increasing the
expression of Sox9 (H. S. Sul et al., 2000; Y. Wang, K.-A. Kim, et al., 2006; Y. Wang and
Hei Sook Sul, 2009; Cawthorn et al., 2012). This process is regulated by several, temporal
transcriptional events, including the sequential expression of adipogenic CCAAT/enhancer
binding protein transcription factors C/EBPα, C/EBPβ, C/EBPδ and Pparγ (Farmer, 2006).
Differentiation is initiated by adding a hormonal cocktail, which induces Cebpβ and Cebpδ.
Subsequently, Cebpα and Pparγ are expressed, leading to terminal differentiation of mature
adipocytes, characterized by the expression of Fabp4, Lep and other markers (E. D. Rosen,
Hsu, et al., 2002; E. D. Rosen and Spiegelman, 2006; Zamani and Chester W. Brown, 2011).
In the process of transition from mitotic clonal expansion to terminal differentiation, FOXO1
is activated, which in turn activates p21 (a cell cycle inhibitor), leading to the 2nd growth
arrest and permitting terminal differentiation (Fajas, 2003; Nakae et al., 2003; Seoane et al.,
2004; Munekata and Sakamoto, 2009) (Figure 2.1). During adipogenesis, mitochondrial
number and mitochondrial activity greatly increases.
The mature adipocyte is a key regulator of energy and glucose homeostasis. The
primary function of the adipocyte is to accumulate triglycerides during excess caloric intake
and to release non-esterified free fatty acids (NEFA) during periods of energy demand.
Adipocytokines secreted by the adipocyte and other cell types within adipose tissue play a
crucial role in maintaining energy homeostasis. Mature adipocytes regulate numerous key
factors including regulating the balance between the fatty acid synthesis (lipogenesis) and
breakdown of triglycerides (lipolysis) and synthesis of non-esterified fatty acids (NEFA).
Hormone sensitive lipase (HSL) and adipocyte triglyceride lipase (ATGL) are the main
lipases for the regulation of lipolysis (Holm, 2003)). β-adrenergic stimulation of lipolysis
requires HSL activation (Haemmerle et al., 2002; Fortier et al., 2004; Duncan et al., 2007;
Frühbeck et al., 2014). Also, cAMP-dependent PKA-mediated phosphorylation of PERILIPIN and HSL leads to the conformational change that allows the contact of triglycerides
with HSL, which releases NEFA and glycerol for transport to the cell surface by fatty acid
binding proteins (Coe, Simpson, and Bernlohr, 1999). NEFAs that are taken up by adipocytes
during times of energy excess are esterified and form triglycerides (Lehner and Kuksis, 1996;
Miyoshi et al., 2006). Insulin inhibits lipolysis through phosphorylation (Evan D. Rosen
and Ormond A. MacDougald, 2006).
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Figure 2.1: Adipogensis. Mesenchymal stem cells and its delineation into
Myf5- or Myf5+ precursors and further differentiation into myocytes or
brown adipocyte or white or brite adipocytes. Image generated with
biorender.

18

Chapter 2. Literature Review

2.15

19

Activin Signaling and Transcription Factors (SMAD2 and
SMAD3) Regulate Adipogenesis

Several TGF-β family members including activins A and B play an important role in preadipocyte determination, adipocyte differentiation and function, and consequently, they
have direct effects on adipose tissue function (C. W. Brown, L. Li, et al., 2003; Hirai et al.,
2005; L. Li et al., 2009; Namwanje and C. W. Brown, 2016; Xue et al., 2016; Wankhade et al.,
2018). Some of the ligands in this family such as BMP2, BMP4, BMP7 stimulate adipocyte
differentiation are also involved in the commitment of MSC precursors (C3H10T1/2) or
3T3-L1 preadipocytes to the adipocyte lineage (Tang, Otto, and Lane, 2004; Bowers et al.,
2006). BMP7 supports brown adipogenesis by inducing the expression of genes involved in
mitochondrial biogenesis, while TGF-β and activins have inhibitory roles on adipogenesis
(Y.-H. Tseng et al., 2008; Zamani and Chester W. Brown, 2011). Activins A and B exert
pleiotropic actions on adipose tissue function (C. W. Brown, L. Li, et al., 2003; Hirai et al.,
2005; L. Li et al., 2009; Xue et al., 2016; Wankhade et al., 2018; M. J. Lee, 2018). Activin A is
highly expressed during the early stages of adipogenesis while activin B is highly expressed
in mature human adipocytes. Taken together, activin A and B play prominent roles in
adipose tissue biology and energy metabolism (Sjöholm et al., 2006; Carlsson et al., 2009;
Dani, 2013). Activin signaling during adipocyte differentiation leads to the activation of
SMAD2/SMAD3 to inhibit the expression of adipogenic genes, Cebpα, Cebpβ, Cebpδ and
Pparγ (Darlington, Ross, and O. A. MacDougald, 1998). Activin A promotes preadipocyte
proliferation and inhibits SMAD2-mediated differentiation during the early stages of human
adipocyte progenitor differentiation and in mouse 3T3-L1 cells by reducing Pparγ and Cebpα
expression (Hirai et al., 2005; Horie et al., 2008; Zaragosi et al., 2010). Hence, downregulation
of activin A is required for the commitment of precursors to the adipocyte lineage (Dani,
2013). Also, activin A/SMAD2 signaling inhibits preadipocyte differentiation and promotes
self-renewal of adipose progenitors by inducing expression of Nanog (Q. Zhu et al., 2018).
Additionally, activin B inhibits lipolysis in 3T3-L1 cells (Magnusson et al., 2010). Activin
can also compete for type II receptors used in BMP pathways that phosphorylate ALK2,
thereby antagonizing BMP-induced, SMAD1/5-mediated signaling or in some contexts
activating the same pathway. Whether activin-associated SMAD1/5-mediated effects occur
in adipose remains unknown (Olsen et al., 2020), image partially adapted from Olsen et al.,
2020, biomolecules and generated with biorender (Figure 2.2).

2.16

Structure and Function of SMAD2 and SMAD3

In mammals, there are 8 SMAD proteins designated SMAD1-8. These proteins are divided
into three groups: the receptor-mediated SMADs (R-SMADs), common mediator SMAD
(Co-SMAD), and the inhibitory SMADs (I-SMAD). The R-SMADs include SMAD1, SMAD2,
SMAD3, SMAD5 and SMAD8 and are divided into two main branches such that SMAD2
and SMAD3 are transducers for TGF-β-like ligands (TGF-β, activins and nodal) and SMAD1,
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Figure 2.2: SMAD-Mediated Activin Signaling Pathway. Activin A and B
bind to the type II receptors, ActRIIA and ActRIIB which phosphorylates
ActRI (ALK4/7). Active ALK4/7 further lead to phosphorylation of SMAD2
and SMAD3. pSMAD2 and pSMAD3 makes a complex with SMAD4 and
translocate into the nucleus and regulate transcription of adipogenic genes.
Activin inhibit adipogenesis via SMAD2/3 pathway by suppressing the
expression of Pparγ and Cebpα, the master regulator of adipogenesis.
Activins can also interact with BMP-receptor type I, ALK2 which can
phosphorylate SMAD1/5. Phosphorylated SMAD1/5 interacts with SMAD4
and regulates the transcription of target genes which may involve in
adipogenesis. Image partially adapted with open access permission from
biomolecules, Olsen et al., 2020 (Olsen et al., 2020) and generated with
biorender.
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5 and 8 are substrates for the BMP like ligands. The Co-SMAD, SMAD4 a consistent
component of R-SAMD-Co-SMAD complexes and associates with all R-SMADs in both
TGF-β and BMP branches. Inhibitory SMADs, SMAD6 and SMAD7, block the binding of
R-SMADs with Co-SMAD or target ligand receptors complexes for degradation in both
TGF-β and BMP branches (Zamani and Chester W. Brown, 2011).
SMAD2 and SMAD3 are nearly identical proteins of ≈500 amino acids, sharing ≈92%
amino acid similarity. SMAD proteins consists of two conserved regions known as the
N-terminal Mad homology domain (MH1) and C-terminal Mad homology domain (MH2)
coupled by linker region. SMAD2 and SMAD3 proteins have 66% amino acid similarity at
the MH1 domain except SMAD2 has a unique highly conserved 30 amino acid E3 insert
in the MH1 domain which is absent in SMAD3. Therefore, SMAD2 has two isoforms,
encoded by alternatively spliced transcripts, one lacking the E3 insert (SMAD2β isoform).
In contrast, SMAD2 and SMAD3 exhibit 96% amino acid similarity in the MH2 domains.
During signal transduction, SMAD2 and SMAD3 form homodimers or heterodimers and
associate with SMAD4 (Aragon et al., 2019). The R-SMADs and SMAD4 have N-terminal
nuclear localization signals (NLS) in the MH1 domain while SMAD4 has an additional
nuclear export signal (NES) in the linker region (Z. Xiao et al., 2003; K. A. Brown, Pietenpol,
and Moses, 2007) (Figure 2.3).
N- terminal MH1 domains of SMAD2 and SMAD3 are involved in DNA binding
while the C-terminal MH2 domains interact with nuclear proteins including transcriptional
co-activators (P300/CBP), co-repressors (p107, c-SKI) and other transcription factors (FOXO
1, 3, 4) which regulate the transcription of TGF-β family downstream target genes (X.
Shen et al., 1998; W. Xu et al., 2000; Seoane et al., 2004; Feng and Derynck, 2005). ISMADs lack MH1 domain (Y. Shi and J. Massagué, 2003). Though it has been stated that
SMAD2 and SMAD3 show 92% sequence similarity, they have acquired different functions
during development. SMAD3 alone or in a complex with SMAD4 and other interacting
partners can bind to the DNA directly and regulate the expression of key genes required
for development, while SMAD2 homodimer fails to bind directly to DNA in the absence
of SMAD4 because of the additional 30aa E3 insert. Hence, SMAD2/SMAD4 heteromer
requires interaction with other transcription factors to form DNA-binding complexes (Joan
Massagué, 2000; Moustakas, Souchelnytskyi, and Heldin, 2001; Dijke and C. S. Hill, 2004).
Consistent with this idea, FOXH1, POU5F1/OCT4 and FOXO1, 3, and 4 proteins have
all been shown to interact with SMAD2 and help to bind to DNA (Seoane et al., 2004;
Mullen et al., 2011; Aragon et al., 2019). This indicates that SMAD2 and SMAD3 have
evolved unique and non-overlapping functions depending on the interacting partners with
whom SMAD2 and SMAD3 engage. Therefore, SMAD2 and SMAD3 may function similarly,
with functional overlap in some tissues and cellular contexts but may also have unique
and non-overlapping function in other tissues depending on the type of SMAD complex
(homotrimeric/heterotrimeric). The specific composition of these SMAD complexes has
not been determined for several cell types. Alternative composition of SMAD complexes
was further supported by Aragon et al. 2019 when they showed that SMAD2 can also bind
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Figure 2.3: Structures of SMAD3, SMAD2, SMAD2β and SMAD4.
SMAD3 and SMAD2 are highly homologus protein having N-terminal Mad
homology domain (MH1) and C-terminal Mad homology domain (MH2)
coupled by linker region. MH1 domain of SMAD2, SMAD3 and SMAD4
contains nuclear localization signals (NLS) in MH1 domain while
common-smad, SMAD4 contains NLS and nuclear export signal (NES)in the
linker region. MH1 domain of SMAD2 and SMAD3 differs from each other
by 30AA E3 insert in SMAD2 which is absent in SMAD2β. MH2 domain has
SSXS phosphorylation site which are the direct targets of activin/TGF-β
signaling. Image generated with biorender.
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to the DNA directly. To do so SMAD2 exists in alternative, tri-dimensional conformations,
one with a correctly folded E3 insert that can directly bind to DNA (Aragon et al., 2019).
SMAD3/SMAD4 complexes bind multiple 50 -AGAC0 sequences known as SMAD binding
elements (SBEs) at the promoter of target genes using the MH1 domain (J. Kim et al., 1997;
Yigong Shi et al., 1998). Collectively, depending on the affinity of interacting transcription
factors with SMAD2 or SMAD3 and whether activin or TGF-β signaling occurs, SMAD2
and SMAD3 function differently. This is illustrated by EVI, which functions as a repressor
by interacting with SMAD2 during activin signaling and also as a repressor by interacting
with SMAD3 during TGF-β signaling (Kurokawa et al., 1998; Allison et al., 2008).

2.17

SMAD2 and SMAD3 in Development and Disease

Although SMAD2 and SMAD3 are closely related proteins, they have either overlapping
or distinct roles depending on the tissue or cell type where these proteins are expressed.
In most cell types, SMAD2 and SMAD3 are co-expressed and SMAD2 and SMAD3 global
knockout mice have different phenotypes. Both proteins differ from each other in several
ways including cellular localization, as activated SMAD2 forms a high affinity complex with
SMAD4 that translocates to the nucleus for transcriptional activities, while SMAD3 remains
in the nucleus even in the steady state, has weak affinity for SMAD4 and has distinct
roles in embryonic development (L. Liu et al., 2016). It has been reported that SMAD2
and SMAD3 regulate many biological processes during embryogenesis and adipose tissue
homeostasis, including cell growth, differentiation, and cell fate determination. SMAD2 and
SMAD3 have distinct functions such as the prominent role of SMAD2 during embryonic
development (Kriseman et al., 2019). Smad2 knockout mice die in utero (7.5) due to defects
in mesoderm formation and defects in gastrulation (Nomura and E. Li, 1998; Waldrip et al.,
1998; Weinstein et al., 1998; Ju et al., 2006). In contrast to Smad2, Smad3 global knockout
mice are viable and fertile however these mice are smaller than their control littermates
and undergo growth retardation postnatally with immune defects, forelimb malformation
and colorectal cancer. 70% of mice die between 1 to 3 months and rest die by 8 months of
age (Q. Zhu et al., 2018; Ashcroft et al., 1999; Datto et al., 1999; Yang et al., 1999; C. K. Tan,
Leuenberger, et al., 2011). Conditional deletion of individual Smad2 or Smad3 in the ovary,
using Amhr2Cre caused a moderate change in female fertility, while combined deletion of
Smad2 and Smad3 using Amhr2Cre led to significant reduction in female fertility. Using
Progesterone receptor Cre (Pgr Cre), uterine selective Smad2/3cDKO mice displayed infertility
due to endometrial hyperproliferation starting at puberty, which ultimately resulted in
uterine cancer with 100% mortality by 8 months (Q. Li, Pangas, et al., 2008; Kriseman
et al., 2019). Furthermore, it has been shown that in liver, deletion of Smad2 or Smad2/3
using Albumin-Cre does not impair liver function, indicating that SMAD2 and SMAD3 are
not required for normal liver function. However, hepatocytes isolated from Albumin-Cre,
Smad2cKO proliferate faster than wildtype. This indicates SMAD2 functions as a negative
regulator of hepatocyte proliferation in liver in vivo which is consistent with findings in a
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liver injury model. Like Smad2, Smad3cKO showed a similar trend in vitro but not in vivo (Ju
et al., 2006).
With excess calories, in addition to white adipose tissues, ectopic fat deposition
can take place in other metabolically active organs such as pancreas, liver, and muscle.
To examine the role of TGF-β/SMAD3 in different organs, Sushil Rane’s group studied
all metabolically relevant organs. Yadav et al., (Yadav, Quijano, et al., 2011), Tan et al.,
(C. K. Tan, Leuenberger, et al., 2011) and Tsurutani Y. et al (Tsurutani et al., 2011) have
demonstrated that the global knockout of Smad3 in mice protects them from diet-induced
obesity and improves their overall metabolic profile including glucose tolerance and insulin
sensitivity with reduced WAT mass. Also, Smad3 global knockout mice had altered phenotypic characteristics of WAT, including multilocular, UCP1 positive adipocytes and other
molecular features of brown adipose tissue, with increased mitochondrial biogenesis (Yadav,
Quijano, et al., 2011). SMAD3 negatively regulated serum IRISIN secretion by reducing the
expression of FNDC5 and PGC-1α at the transcriptional as well as protein levels in skeletal
muscle (Tiano, Springer, and Rane, 2015). Additionally, deletion of Smad2 in pancreatic
β-cells resulted in islet cell hyperplasia with impaired INSULIN secretion (Nomura, H. L.
Zhu, et al., 2014), where as Smad3 deletion enhanced insulin secretion by regulating genes
involved in pancreatic β-cell function (H. M. Lin et al., 2009). Liver-selective deletion of
Tgf-βRI or Smad3 suppressed liver gluconeogenesis under normal physiological conditions
and type2 diabetes via PP2A-AMPK-FOXO1. Additionally, inhibition of TGF-β/SMAD3
signaling by shSmad3, or TGF-β (Hildebrandt et al., 2009) inhibitors (SB431542) in vitro
resulted in suppressed glucose levels in hepatic cells (Yadav, Devalaraja, et al., 2017).

2.18

Role of Microbiota on Obesity

Gut microbiomes play an important role in metabolic disease, including obesity, type 2
diabetes and inflammation (Awan, Meurling, and O’Shea, 2021). The microbiome regulates
host energy homeostasis, including adipose tissue induced by HFD. High fat diet promotes
metabolic disorders by altering the gut microbial community including the changes in
the proportion of Bacteroidetes, Firmicutes and probacteria. Damage to the gut barrier
and overall changes in gut microbiome contribute to obesity and development of other
metabolic diseases such as type2 diabetes in mice (C. Zhang et al., 2012). Bacteroidetes and
Firmicutes comprise the major gut microbiome and their proportion is a major determinant
in obesity (Turnbaugh, Ley, et al., 2006). Studies have shown dose-dependent effects
of HFD on gut microbial changes (Carmody et al., 2015). In a rat model, it has been
shown that obese rats have different gut microbiota than obesity resistant rats on the same
HFD. Transplantation of gut microbiome from obese mice into germ free mice resulted in
an obese phenotype (Duca et al., 2014). Additionally, changes occur in the composition
of the microbial community under prolonged cold exposure resulting in an increase in
the Firmucutes/ Bacteroidetes ratio by 3.5 fold compared to mice at room temperature
(Chevalier et al., 2015). The mechanisms involved in the observed phenotype including
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inflammation, intestinal permeability and upregulated lipogenesis are dependent upon the
HFD composition. Additionally, gut microbiota are crucial in modulating lipogenic genes
(E. Y. Huang et al., 2013). Targeting gut microbiome may reduce the risk of obesity and
associated metabolic disease (Murphy, Velazquez, and Herbert, 2015).
The gut microbiome communicates with adipose tissue, regulates energy homeostasis, and contributes to the development of obesity. Juge et al. suggested that the composition
and activities of the gut microbiome contributes to obesity. The gut microbiome regulates
absorption of nutrients in the intestine and regulates adipose tissue energy homeostasis and
thermogenesis through short-chain fatty acids (SCFAs)(Thursby and Juge, 2017; H. Xiao and
Kang, 2020). Bacterial metabolites such as SCFAs and bile acids influence the function of
adipose tissue and contribute to the regulation of energy homeostasis of adipose tissue. Gut
microbiome produced butyrate, a SCFA, impacts the thermogenic activity of brown adipose
tissue, as administering sodium butyrate to microbiota-depleted mice partially rescued
impaired thermogenesis and promoted fatty acid oxidation. Studies also demonstrated
that butyrate from the gut is delivered to the brain more so than other tissues and that
gut-derived butyrate activates WAT britening through a gut-brain circuit but may not exert
direct effects within adipose (B. Li et al., 2019).
Genetic manipulation or cold exposure alters the diversity of gut microbiota in mice,
altering microbial metabolites (butyrate and other SCFAs) and conferring thermogenic
properties. Transfer of the cold microbiota in germ-free mice resulted in thermogenic ability
with a corresponding increase in energy expenditure. Additionally, transplantation of cold
microbiota induced browning, promoted thermogenesis in WAT and improved insulin
sensitivity (Chevalier et al., 2015; Zi˛etak et al., 2016). Additionally, butyrate increased
energy expenditure and mitochondrial activity by increasing Pgcα in brown adipose tissue.
Further, butyrate treatment increased energy expenditure genes including mitochondrial
genes and browning genes such as Ucp1, Pgc1α , Cpt1b, Cox7a in WAT and BAT (D. Wang
et al., 2020).
To understand the mechanism(s) underlying the role of the microbiome in obesity, the
microbiome of human twins (one obese and one lean) were transplanted into germ free mice.
These mice were fed low fat, high carbohydrate diet. The recipient mice of obese microbiota
gained more fat, with more Firmicutes expressing genes involved in nutrient transporters. In
contrast, mice receiving lean microbiota, with more Bacteroidetes expressing genes involved
carbohydrate metabolism. These difference in body fat were correlated with a different
capability for fermenting nutrients such as lean mice had more fermentation of SCFAs
while obese mice most of the metabolites from branched chain amino acid (Turnbaugh,
Ley, et al., 2006; Turnbaugh, V. K. Ridaura, et al., 2009; Turnbaugh, Hamady, et al., 2009;
Vanessa K. Ridaura et al., 2013; O’Keefe, 2016; H. Xiao and Kang, 2020).
The relationships among the gut microbiome, obesity, and TGF-β/SMAD3 signaling
are emerging. Smad3 global knockout mice exhibit growth retardation and develop colorectal cancer. Daniel et. al demonstrated the link between the development of colon cancer and
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gut microbiome, specifically Helicobacter in Smad3 global knockout mice. Smad3 deficient
mice with colon cancer displayed functional changes in the gut microbiome. Using an omics
approach, this group has shown the functional differences/shifts in the microbiome, specifically the bacterial communities involved in distinct pathways including colon cancer, LPS
production, SCFA metabolization and oxidative phosphorylation in Smad3 global knockout
mice with or without inoculation of H. hepaticus. Upregulation of Bacteroidaceae by 1.89
fold was observed alone and 2.26 fold upregulation with H. hepaticus in Smad3 global
knockout mice compared to wild type mice. A similar trend was observed at the phylum
level of Bacteroidetes. The Smad3 deletion associated inflammation is not the only cause
of tumor formation, as Helicobacter alone is strongly associated with colon inflammation
and Helicobacter triggers inflammation in Smad3 global knockout mice. In addition to
Helicobacter, several other bacterial species are involved in the development of colon cancer
in Smad3 global knockout mice (Daniel et al., 2017).
The contribution of intestinal microbiota in inflammatory bowel disease (IBD) is
known. The TGF-β/SMAD3 pathway is crucial in regulating microbiome associated inflammatory responses and tissue repair and its contribution to IBD. Smad3 global knockout mice
are susceptible to the development of IBD. Microbiome transfer from IBD Smad3 global
knockout mice to germ free mice led to the induction of IBD, with weight loss and more
severe inflammation in the colon in recipient, germ free mice, suggesting a causal role of
microbiome in IBD (Paik et al., 2020).
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Chapter 3
Material and Methods

3.1
3.1.1

In Vivo Assay
Generation of Mice

All animal procedures were carried out in accordance with the UTHSC guidelines on the humane treatment of experimental animals and with the explicit approval of the Institutional
Animal Care and Use Committee (IACUC). Smad2 f lox/ f lox mice used in this study were
purchased from Jackson Laboratories (Ju et al., 2006) (JAX, Bar Harbor, ME, Smad2tm1.1Epb,
Stock No 022074). Adiponectin-Cre (B6;FVB-Tg(Adipoq-cre)1Evdr/J), mice were also purchased
from Jackson Laboratories (Eguchi et al., 2011) (JAX, Bar Harbor, ME, Stock No 028020).
Smad3 f lox/ f lox mice were maintained on (C57BL6/129Sv background) which was obtained
from the Matzuk Laboratory (Matzuk, 1995; Sarjeant and Stephens, 2012). Inhbb-/- (activin
B) null mice and Inhba-/- (activin A) null mice were detailed by Vassalli et al. and Matzuk et
al., respectively (Schrewe et al., 1994; Vassalli et al., 1994; Matzuk, 1995). Smad2 conditional
knockout (Smad2cKO), Smad3 conditional knockout (Smad3cKO) and Smad2/3 conditional
double knockout (Smad2/3cKO) mice were generated by crossing Smad2 f lox/ f lox (loxP sites
flanking exon2), Smad3 f lox/ f lox (loxP sites flanking exon 2-3) and Smad2/3 f lox/ f lox mice with
Adiponectin-Cre mice. Smad2 f lox/ f lox , Smad3 f lox/ f lox and Smad2/3 f lox/ f lox mice were used
as a control to compare for Smad2cKO, Smad3cKO and Smad2/3cKO mice respectively. Mice
used for the diet study were 5-week-old males and females. Male and female mice were
housed and fed standard chow diet (Envigo Lab Diet 7912) until age 5 weeks under an approved IACUC protocol by UTHSC animal care unit. The Low fat-diet (LFD, stock D12450J)
and high fat-diet (HFD, stock D12492) feeding started at week 5, purchased from Research
Diets Inc., New Brunswick, NJ. Body weight measurements started at 5 weeks and were
monitored weekly for 23 weeks. Food intake was measured manually at 16 weeks. Smad2
and Smad3 and Smad2/3 conditional knockout mice were generated using Adiponectin-Cre.

3.1.2

Glucose and Insulin Tolerance Tests

Mice were fasted for 6 hours, and baseline blood glucose levels were obtained. 1.5 mg of
glucose/gram of body weight for GTT and 0.75mlU of insulin (humulin-U100)/gram of
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body weight for ITT was injected intraperitoneally, nicked tail vein blood was collected,
and blood glucose was measured at the indicated time points using a glucometer (Contour
Next glucometer and text strips).

3.1.3

Body Composition Measurement

Body composition (fat mass, lean mass and water content in grams) was measured using
an EchoMRI 1100 system (EchoMRI, Houston, TX) and body composition was normalized
to total body weight. Tissues were harvested for molecular analysis and histology.

3.1.4

Indirect Calorimetry (Comprehensive Laboratory Animal Monitoring System, CLAMS)

Smad2/3cKO male and female mice on HFD were weighed and housed individually in a
metabolic cage with water bottle and ad libitum food, compatible for CLAMS (Columbus
Instruments) at 22°C. Instrument calibration was done against a standard gas mixture
of oxygen, carbon dioxide, and nitrogen. Mice were in acclimation period to the new
environment for first 24-hours and data collection began after 24-hours of acclimation period
and continued for 7 days following 12:12h light/dark cycle. Oxygen consumption (VO2 ),
carbon dioxide production (VCO2 ), total energy expenditure (TEE), respiratory exchange
ratio (RER) and physical activity were measured via open-circuit indirect calorimetry by
Oxymax software (Columbus Instruments). In fasting conditions, initial 6-hours data was
excluded from the time of fasting. Total energy expenditure (TEE) was calculated using
Lusk equation(Lusk), TEE (heat)= (3.815+1.232 X RER) X VO2 . Total physical activity
was calculated as the combined number of infrared beam breaks in both X and Y axis.
Ambulatory activity was calculated by combining the number of consecutive X and Y axis
beam breaks.

3.1.5

DNA Isolation and Genotyping

Genomic DNA was isolated from tail biopsies using standard alkaline lysis procedure.
Go Taq Green master mix (Promega. Cat M7123) with addition of 2mM MgCl2 based
genotyping was performed using a Veriti 96-well Touch Thermal cycler (Applied Biosystems Life technologies). The Smad2 floxed allele was detected using the primers following
the protocol from Jackson Laboratories: Smad2 forward primer: AGC TTG AGA AAG
CCA TCA CC and reverse primer GAC CAA GGC GAA AGG AAA CT. The product size was 350 bp for WT and 400bp for the floxed allele and Smad3 forward primer:
CTCCAGATCGTGGGCATACAGC and reverse primer GGTCACAGGGTCCTCTGTGCC.
The product size was 200 bp. The activin A null allele was detected using the primers
HPRT-A forward - 50 - GACCTCTCGAAGTGTTGGATAC-30 and HPRT-B reverse - 50 CTTGCGCTCATCTTAGGCTT-30 , PCR product size 170 bp. The following amplification scheme was used with 5% DMSO in the above PCR mix: 98°C for 5 min for 1
cycle; 98°C for 30 sec, 50°C for 30 sec, 72°C for 1 min for 35 cycles; 72°C for 10 min
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and then 4°C to hold. The corresponding WT allele was detected using the primers
BA EXON3 forward - 50 -ACAGAACCAGGACCAAAGTCACCA-30 ; BA EXON3 reverse,
50 -TCCAGTCATTCCAGCCAATGTCCT-30 , the product size 560 bp. WT PCR amplification reaction was performed without DMSO and the annealing temperature was set
at 58°C. Presence of either HPRT or WT band alone indicated the null allele for activin
A and WT respectively; however, presence of both bands indicated Het samples for activin A. The activin B null allele was detected using the multiplex PCR assay primers (P1,
P2 and P3): P1 BB 50 PRO 2 50 -ATGGTCACGGCCCTGCGCAA-30 , P2: BB 30 Exon1 50 CAAAGCTATGATCTCGGAGA-30 and P3: Neo forward 50 - CCTTCTTGACGAGTTCTTCT30 . These 3 primers generated PCR products of 150 bp or 500 bp, corresponding to the WT
and activin B null alleles, respectively. PCR amplification reactions were carried in the
following conditions: 35 cycles consisting of 50 sec of annealing at 55°C (no DMSO) and the
rest was similar to above PCR conditions.

3.1.6

Tissue Collection

Visceral and subcutaneous adipose tissues were dissected, weighed, and processed for
RNA, protein and histology.

3.1.7

Histology

Visceral and subcutaneous WATs were fixed in 4% paraformaldehyde at 4°C overnight,
embedded in paraffin and sectioned at 5 microns. After deparaffinizing, rehydrated sections
were stained with hematoxylin and eosin (Cat. No. H-3502, Vector Laboratories) following
the vendor’s protocol. Images were acquired using EVOS FL Auto Imaging System (Thermo
Fisher, Foster City, CA).

3.1.8

RNA Isolation and Gene Expression Analysis

Total RNA was isolated from visceral and subcutaneous adipose tissues or undifferentiated
and differentiated cells using the trizol method (Invitrogen). cDNA was prepared according
to the manufacturer’s protocol using the Invitrogen Superscript IV First-Strand Synthesis
System kit (Invitrogen 18-091-050). Quantitation of gene expression was performed by
real-time RT-PCR (Quant Studio 6 Flex Real-Time PCR System, Applied Biosystems) using
SYBR Green master mix (Applied Biosystems), normalized to Cyclophilin B. The quantitative
analysis was performed using the standard delta-delta ct method and results are shown as
relative fold change in gene expression compared to wild type. Analysis of quantitative
PCR data was accomplished using Relative Expression Software Tool (REST) 2008 (Corbett
Research, Technical University, Munich, Germany) and GraphPad. The REST analysis
addresses issues regarding the measurement of uncertainty in expression ratios inherent in
quantitative PCR analysis by using randomization and boot-strapping techniques, including
50,000 hypothesis tests to achieve a high level of consistency.
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Western Blot Analysis

Protein lysates were prepared from tissues, undifferentiated and differentiated MEFs and
preadipocytes after homogenization in tissue or mammalian protein extraction reagent
(TPER for tissue (catalog 78510) and mPER, for cells (catalog 78501)), supplemented with
phosphatase and protease inhibitors. Cell lysates were cleared by spinning down at 17000g
for 30 minutes at 4°C, then placed on ice to separate lipids from tissue and re-centrifuging for
10 minutes. Protein quantity was measured using the Pierce BCA-protein assay kit (Thermo
Fisher Scientific Inc.). Equal amounts of protein (30 µg/ well) were loaded on 4-12% SDS
polyacrylamide gels and transferred to PVDF membranes. Blots were blocked in 5% nonfat
dried milk in tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hr. Membranes were
washed briefly with TBST, then incubated overnight with the following primary antibodies
at 4°C: SMAD2 (Cell Signaling, CS3122), SMAD3 (Cell Signaling, CS9523), pSMAD2 (Cell
Signaling, CS3108, CS3104), pSMAD3 (Abcam, ab52903, Cell Signaling, CS9520), SMAD2/3
(Cell Signaling, CS8685) and GAPDH (Santa Cruz, SC32233) in 2% BSA diluted in 1X TBST.
The following day, membranes were washed with TBST three times, 10 minutes each, then
incubated with HRP- conjugated secondary antibody (Cell Signaling, 7074, Santa Cruz,
SC516102) for 1 hr. Membranes were then washed thrice with TBST. GAPDH protein
was used as loading control for each assay. Finally, protein bands were detected using a
chemiluminescence imager (Amersham imager 600).

3.2
3.2.1

In vitro Assay
Mouse Embryo Fibroblasts (MEFs) Isolation and Cell Culture

From timed mating, MEFs were isolated from E13.5 embryos of WT and activin dKO
mice. First, embryos were isolated and transferred to a new dish (one dish per embryo to
avoid genotyping cross-contamination) containing 1X PBS (pH7.4). Using sterile forceps,
the head, tail, limbs and abdominal contents were removed. Tail/limbs were saved for
genotyping. The remaining portion of the embryos were transferred into a sterile Eppendorf
tube containing 0.25% trypsin-EDTA. The tissues were crushed thoroughly with forceps.
Tubes were kept on ice during collection and kept at 4°C overnight. The tail/limb samples
were processed for genotyping of wild type and activin dKO mice. MEFs were processed as
follows: All tissues that were kept at 4°C were placed at 37°C for 15 minutes. Then tube
exteriors were sprayed with 70% ethanol and using a 1ml pipette filtered tip, the tissues
were gently moved up and down 3 times and transferred to 15 ml tubes containing 5 ml
basic medium (1X DMEM supplemented with 10% FBS (Hyclone), sodium pyruvate (1
mmol/L), 1% Penicillin/Streptomycin (100X), and L-glutamine (2 mmol/L). A vigorous
mixing with a 5 ml pipette was then performed to disintegrate the tissues, which were then
filtered at 100 µm into a sterile 50 ml conical tubes. The filtered suspensions containing
MEF cells were transferred to 10 cm culture dishes, medium adjusted to a total of 10 ml,
and were cultured at 37°C in a 5% CO2 incubator. The following day, fresh basic medium
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was replaced to remove the dead cells and cultured for another 3 to 4 days. After reaching
near confluency, the cells were trypsinized and seeded for RNA and protein. Passages
were limited to a maximum of three. Isolated MEFs were cultured and set up for adipocyte
differentiation assays. Cells were seeded at confluence and grown for two days to achieve
growth arrest. Cells were induced to differentiate with adipocyte differentiation medium
(Cell Applications, catalog 811D-250) and harvested for protein on day 8 when >90% of the
cells were differentiated.

3.2.2

Preadipocyte Isolation and Differentiation Assay

Visceral and subcutaneous preadipocytes were isolated from visceral and subcutaneous fat
pads from wild type mice on postnatal days 12-16. Fat pads were digested in 0.2 mg/mL
collagenase type II (catalog 17101015) in KRBH buffer containing 4% fatty acid-free BSA
while shaking for 20-30 minutes at 120 RPM at 37°C. Cells from the digested fat pads
were filtered at 100-microns and centrifuged at 800g for 10 minutes at room temperature.
1mL of red blood cell (RBC) lysis buffer was added to the cell pellet for 1-3 minutes at
room temperature and diluted in PBS. Cells were filtered at 70-microns, centrifuged, and
resuspended in 1X DMEM media supplemented with 10% FBS (Hyclone), sodium pyruvate
(1 mmol/L), 1% Penicillin/Streptomycin (100X), and L-glutamine (2 mmol/L).
200K cells were seeded in 12 well plates and incubated for two days to achieve
confluence and to attain contact inhibition. Cells were then induced with 10% FBS media
containing induction cocktail (1uM dexamethasone, 0.5mM isobutyl methylxanthine, 10
ug/ml insulin and 1nM T3 with or without treatment (see below) for the first three days.
Maintenance media (differentiation media) was added with 10 ug/mL of insulin+1 nM T3
with or without 40ng/mL of activin (R and D, catalog 338-AC-010), 5uM SB431542 (Millipore, catalog 6164615MG), and 3uM SIS3 (Tocris Bioscience, catalog 52-911-0) mentioned in
chapter 4. Fresh Maintenance media was added every two days with 10 ug/mL of insulin
and 1 nM T3 until harvest. Differentiation efficiency was evaluated by the morphological
appearance of differentiated preadipocytes and by staining with Oil Red O and BODIPY on
day 8.

3.2.3

Immunofluorescence

MEFs differentiated in chamber slides were harvested on day 8 and fixed with 4% paraformaldehyde for 15 minutes at RT followed by washing with 1X PBS (pH7.4). Cells were
permeabilized with 0.2% triton X-100 in 1X PBS (pH7.4) for 10 minutes followed by washing
with 1X PBS (pH7.4) twice. Cells were blocked for 5 minutes in 3% fetal bovine serum
(FBS) diluted in 0.1% triton X-100 in 1X PBS (pH7.4) and incubated with primary antibody
UCP1 (Abcam ab10983) at 1:200 dilution overnight at 4°C. Next day, cells were washed
with 0.1% triton X-100 in 1X PBS (pH7.4) three times for 15 minutes each and incubated
with secondary antibody conjugated with Alexa 568 fluorochrome diluted (1:500) in 3% FBS
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with 1µl/ml DAPI and incubated for 1 hour at RT. Cells were washed thrice followed by
mounting the cells with mounting medium (Vector laboratories, Prolog Gold).

3.2.4

Proliferation Assay

Visceral and subcutaneous preadipocytes were seeded in a 96 well plate. After overnight
settling, next day morning cells were treated with vehicle (DMSO) or Activin A or SB431542
or SIS3 and incubated for 48hr. Cells were treated every 24hrs and total two dose of
treatment were given. Quantification of cell proliferation assay was performed using MTT
based cell proliferation kit (Sigma 11465007001). Cells were also counted to ascertain the
results. The assay was conducted according to the manufacturer protocol to ascertain the
proliferation of wild type mouse preadipocytes.

3.2.5

Flow Cytometry

Preadipocytes were seeded in a 12 well plate. After overnight settling, next day morning
cells were treated with indicated concentration of vehicle (DMSO) or Activin A or SB431542
or SIS3 and incubated for 48hr similar to proliferation studies. At the end of the experiment,
cells were harvested by trypsinizing, resuspending in 10% FBS media followed by centrifugation at 1000 RPM for 5 minutes. Cells were washed with cold PBS at 500g for 3 minutes
twice and resuspended the cells in 100uL of 1x annexin-binding buffer. Added 5uL of FITC
annexin V and 1uL of 100ug/mL propidium iodide (PI). Cells were incubated at room
temperature for 15 minutes. Added 400uL of 1X annexin binding buffer after incubation
and mixed gently and stored the sample on ice until stained the samples by flow cytometry.
Hydrogen peroxide was used as a positive control. Negative control had no inducing agent.

3.2.6

RNA-Seq Library Prep

Total RNA was isolated from undifferentiated and differentiated mouse embryonic fibroblast cells (MEFs) using the trizol method (Invitrogen). Submitted RNA samples from
differentiated groups was subjected to analysis on an Agilent Bioanalyzer and spectrophotometric analysis to determine RNA quality. After passing this initial screening 500ng of total
RNA will be enriched for polyA RNA or depleted of rRNA then used to prepare libraries for
sequencing using the NEB Next Directional RNA Library Prep Kit for Illumina. Libraries
amplified for 9-15 cycles, depending on original starting material, as the final step of library
preparation. Before sequencing, small aliquots of this material will be quantified by qPCR
utilizing the KAPA Library Quantification kit. Quantification data from qPCR are used to
balance the barcodes for final pooling before sequencing. Following this final pooling the
library pools are sized to a target size of 300bp on a Pippin Prep instrument. The sized
libraries are examined on an Agilent High Sensitivity DNA chip, quantified using real-time
PCR, and used for sequencing on the Illumina NextSeq 500 at UTHSC core.
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RNA-Seq Processing, Sequencing, and Analysis of RNA-Seq Data

All fastq files were gathered from the sequencer, and quality assurance was performed using
FASTQC. Reads were trimmed to remove any nucleotide with a PHRED score < Q20, and
the trimmed FASTQ files were aligned to the Genome Reference Consortium Mouse Build
38 mm10 mouse fasta reference library using RNA STAR. Once aligned, the SAM files were
collected and mined for the read count information of each gene present in the reference
file. 30-40 million reads were recorded per sample. Read counts were normalized using
Median Ratio normalization method and across the entire experiment. Principle component
analysis and Pearson’s coefficient plots were performed on the normalized transcriptome
profile. Differential gene expression between wildtype and double knockout activin cells
was accessed using false discovery rate (FDR) < 0.05 and fold change > 1.5. cutoff. A
Wilcoxon’s t test was used to determine significance between conditions, and all genes that
failed to yield a p-value greater than 0.05 were removed. Benjamini and Hochberg false
discovery rate was performed on the trimmed gene list, and all genes failing to yield a false
discovery rate of less than 0.05 were discarded. Heatmaps and scatter plot were generated
using R script. Heat map for browning genes that were upregulated in activin dKO were
plotted using Morpheus software. Pathway analysis was performed using iPathway Guide.
EnrichR was used to analyze cells specific pathways.

3.2.8

Glycerol Estimation

Glycerol estimation was performed according to the manufacturer protocol (Sigma F6428,
G7793) to ascertain the bioactivity of isoproterenol on differentiated adipocytes (MEFs and
3T3-L1) after treatment with ISO. US pharmacopeia reference standard (Sigma 1351005) or
generic version of isoproterenol (Sigma I6504)] was used with different conditions (freshly
prepared or frozen stocks) to eliminate the bias of its bioactivity due to quality or storage.

3.2.9

Microscopy

Images for all in vivo and in vitro experiments were taken using EVOS FL Auto Imaging
System (Thermo Fisher, Foster City, CA). Green, Red and DAPI filters were used for tracking
the lipid and nucleic acid respectively in differentiation experiments. Image J software was
used to quantitate the protein in some experiments.

3.3

Statistical Analysis

GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA) was used for statistical
analysis for each experiment unless otherwise mentioned. Mouse weights study data and
GTT are expressed as mean ± standard error of the mean (SEM). A linear mixed model
two-way ANOVA for body weight (grams) was used to account for repeated measures and
to examine differences in weights among genotypes over time. The Šídák test was used to
control for the multiple comparisons. mRNA levels relative fold changes were calculated
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using the Relative Expression Software Tool 2009 (REST) (Qiagen, Hilden, Germany and
Technical University of Munich, Germany), excel and Graph pad prism. For the remaining
studies, the Mann-Whitney test was used to compare MRI data, such as fat mass and lean
mass, between genotypes. A p value < 0.05 was considered statistically significant for each
experiment. Note: *p < 0.05, **p < 0.005, ****p < 0.00005.
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Chapter 4
SMAD2/3 Differentially Regulate Adiposity and the
Growth of Subcutaneous White Adipose Tissue1

4.1

Introduction

Obesity and the associated metabolic syndrome are major medical problems in the United
States (Chooi, Ding, and Magkos, 2019). Obesity occurs due to an unhealthy increase in
white adipose tissue (WAT) (P. Wang et al., 2008; Jo et al., 2009). Adipose tissue plays
a crucial role in maintaining energy homeostasis. The sustained expansion of WAT dysregulates energy homeostasis by affecting production of adipocytokines such as leptin,
adiponectin and resistin (Gardan, Gondret, and Louveau, 2006; Rabe et al., 2008; Bederman
et al., 2018). Dysregulation of adipocytokine production and release impacts satiety and is a
major determinant of obesity (Unger et al., 2010). Adipose tissue dysfunction occurs with
unhealthy enlargement of adipocytes, associated with inflammation and insulin resistance
(J. M. Rutkowski, J. H. Stern, and P. E. Scherer, 2015; Choe et al., 2016; Longo et al.,
2019). Disproportionate contributions from visceral and subcutaneous WAT depots are
well-described for their important roles in obesity and its co-morbidities (Gesta, Y. H. Tseng,
and Kahn, 2007).
TGF-β and several other ligands in this family including activin A and activin B,
have direct effects on growth and development of a variety of tissues, including adipose,
thereby impacting energy homeostasis (C. W. Brown, Houston-Hawkins, et al., 2000; Choy,
Skillington, and Derynck, 2000; L. Li et al., 2009; C. K. Tan, Leuenberger, et al., 2011; Yadav,
Quijano, et al., 2011; Bonomi et al., 2012; M. J. Lee, 2018). Activins A and B have pleiotropic
effects, impacting preadipocyte proliferation, differentiation, and determining cell fate
(C. W. Brown, L. Li, et al., 2003; Hirai et al., 2005; Zaragosi et al., 2010; Zamani and Chester
W. Brown, 2011; Xue et al., 2016; Q. Zhu et al., 2018). Activins A and B signal through
activin receptors and downstream transcriptional transducers, SMAD2 and SMAD3. In
turn, SMAD2 and SMAD3 regulate the transcription of downstream adipogenic genes
1 Modified:

From final submission with permission from John Wiley & Sons, Inc. (Kumari et al., 2021). “SMAD2
and SMAD3 differentially regulate adiposity and the growth of subcutaneous white adipose tissue”. In:FASEB
journal: official publication of the Federation of American Societies for Experimental Biology.
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(Darlington, Ross, and O. A. MacDougald, 1998; C. W. Brown, L. Li, et al., 2003; Fei
et al., 2010). During adipocyte differentiation the activin signaling pathway phosphorylates
SMAD2/SMAD3, thereby inhibiting downstream transcriptional regulators of adipogenesis,
C/EBPα, C/EBPβ, C/EBPδ and PPARγ (Darlington, Ross, and O. A. MacDougald, 1998;
Choy, Skillington, and Derynck, 2000; Zaragosi et al., 2010; C. K. Tan, Leuenberger, et al.,
2011; Zamani and Chester W. Brown, 2011; C. K. Tan, Chong, et al., 2012).
The functions of activin signaling are well studied in many tissues, including adipose
(K. Tsuchida et al., 2004; Lonardo et al., 2011; Dani, 2013; Latres et al., 2017; Song et al., 2017)
2017, Song, Owusu-Ansah et al. 2017). In previous studies, we have reported that activin
deficiency reduces adiposity and has beneficial effects on energy metabolism (C. W. Brown,
L. Li, et al., 2003; L. Li et al., 2009). Activin A inhibits differentiation via SMAD2 signaling
and promotes self-renewal of human adipose progenitors by inducing expression of Nanog
(Q. Zhu et al., 2018). Although activin A inhibits differentiation in 3T3-L1 pre-adipocytes
and in human adipocyte progenitors (Hirai et al., 2005; Zaragosi et al., 2010; M. J. Lee,
2018), little is known about the role of activins on the differentiation of preadipocytes
derived from mouse adipose depots. SMAD2 and SMAD3, the downstream mediators of
activin signaling, regulate many biological processes including embryogenesis, adipose
tissue growth, adipocyte differentiation, and cell fate decisions (Nomura and E. Li, 1998;
Weinstein et al., 1998; Datto et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al.,
2011; Yadav, Quijano, et al., 2011).
SMAD2 and SMAD3 are closely related proteins, sharing 92% amino acid similarity.
These proteins form homodimers or heterodimers to form functional complexes with
SMAD4 (Aragon et al., 2019). Although there is functional overlap, Smad2 and Smad3 also
have distinct functions such as the critical role of Smad2 during early gastrulation (Nomura
and E. Li, 1998; Waldrip et al., 1998; Weinstein et al., 1998; Heyer et al., 1999; Ju et al.,
2006; Kriseman et al., 2019). In contrast, Smad3 global knockout mice are viable and fertile.
However, Smad3 mice undergo postnatal growth retardation with immunodeficiencies and
shortened lifespan (Y. Zhu et al., 1998; Ashcroft et al., 1999; Datto et al., 1999; Yang et al.,
1999; Q. Li, Pangas, et al., 2008; Tsurutani et al., 2011). Previous studies have demonstrated
that the global knockout of Smad3 protects from diet-induced obesity (DIO) with favorable
metabolic effects, including improved glucose tolerance and insulin sensitivity (C. K. Tan,
Leuenberger, et al., 2011; Tsurutani et al., 2011; Yadav, Quijano, et al., 2011; Yadav and Rane,
2012). However, these studies could not exclude indirect, secondary influences from other
metabolically active tissues such as skeletal muscle, pancreas, and liver, as shown by the
tissue-selective effects of Smad3 deficiency on hepatic gluconeogenesis and pancreatic beta
cell apoptosis (Yadav, Devalaraja, et al., 2017; J. H. Lee et al., 2020).
Previous studies have demonstrated roles for activin A, activin B and SMAD3 on
body composition using a variety of activin and Smad3 alleles (C. W. Brown, HoustonHawkins, et al., 2000; C. W. Brown, L. Li, et al., 2003; L. Li et al., 2009; Bonomi et al., 2012).
However, due to embryonic lethality in Smad2 global knockout mice, SMAD2’s effect on
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adiposity has not been determined. The adipose-selective roles of SMAD3 have also not
been assessed. Accordingly, we investigated the adipose-selective effects of Smad2 and
Smad3 deficiency on adipose tissue development and function.

4.2

Results

4.2.1

SMAD2 and SMAD3 Proteins Exhibit Different Temporal Expression During Adipose Tissue Development

Global Smad3 deletion impacts growth, as mice are smaller at weaning (Datto et al., 1999;
C. K. Tan, Leuenberger, et al., 2011). Preadipocyte proliferation and differentiation begins
at e14.5 in the subcutaneous WAT anlage and approximately 4 days postnatally in visceral
WAT (Sarjeant and Stephens, 2012; Traustadottir et al., 2013). Therefore, we looked at the
total level of SMAD2 and SMAD3 proteins and their phosphorylated forms in both visceral
and subcutaneous WAT from wild type (WT) mice, at 4 time points ranging from postnatal
weeks 1-14 (Figure 4.1 A-B). SMAD2 protein and its phosphorylated form (pSMAD2)
remained unchanged in both visceral and subcutaneous WAT over 14 weeks. In contrast,
SMAD3 protein and its phosphorylated form (pSMAD3) displayed temporal changes in
expression, highly expressed at 1 and 3 weeks but later declining in both visceral and
subcutaneous WAT. This suggests that SMAD3 may contribute to early adipose tissue
development, whereas SMAD2 may contribute additionally to later stages of development
and mature adipocyte function.
We also examined the protein levels of SMAD2 and SMAD3 in WT MEFs induced to
differentiate into adipocytes, in vitro (Figure 4.2 A). While normalized SMAD2 protein levels
did not significantly change, SMAD3 was highly expressed in undifferentiated MEFs as well
as in cells at day 3 post-induction, but substantially declined by day 5, the time at which
most of the cells had assumed the characteristics of mature adipocytes. However, pSMAD2
and pSMAD3 protein levels remained unchanged. Collectively, these findings are consistent
with SMAD3 potentially contributing to the early growth phase of white adipose tissues
and to the early stages of adipocyte differentiation. To determine whether the protein levels
corresponded to changes at the transcriptional level, we measured Smad2 and Smad3 mRNA.
In contrast to the patterns observed at the protein level, both transcripts increased from day
3 to day 8 during the differentiation of WT MEFs, visceral, and subcutaneous preadipocytes
in vitro (Figure 4.2 B-C). Collectively, these mRNA and protein studies are consistent with
SMAD2 and SMAD3 being regulated at the transcriptional, post-transcriptional and posttranslational levels during adipogenesis.

4.2.2

Activins Regulate Phosphorylation of SMAD2 and SMAD3 in Adipogenic
Cells

SMAD2 and SMAD3 are well-established downstream mediators of activin signaling, regulated by their phosphorylation in the presence of activins[19, 23]. Activin-dependent
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Figure 4.1: SMAD2 and SMAD3 Expression in White Adipose Tissues.
(A) Western blot showing temporal changes in protein levels of pSMADs
and SMADs in visceral WAT and (B) in subcutaneous WAT. Note: reduced
expression over time for pSMAD3 and SMAD3 in both depots while no
change in pSMAD2 and SMAD2.
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Figure 4.2: SMAD2 and SMAD3 Expression in Differentiating
MEF-Derived Adipocytes. (A) High protein level of SMAD3 in
undifferentiated MEFs and on differentiation day3, declining by day5 and
day8. No change in protein levels of SMAD3, pSMAD2 or SMAD2 (n=2,
biological replicates). GAPDH was used as a loading control. (B) Smad2 and
mRNA levels during the differentiation of MEFs and (C) Smad2 and Smad3
mRNA levels from visceral and subcutaneous preadipocytes and
differentiated adipocytes isolated from wild type mice. Diff; Differentiated,
Undiff; undifferentiated, Sub; subcutaneous, Vis; visceral.
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Figure 4.3: Effect of Activin Deficiency on SMAD Expression and
Phosphorylation. (A) Western blot of pSMAD2, pSMAD3, SMAD2 and
SMAD3 levels in WT and activin-deficient, fully differentiated MEFs (n=3
biological replicates). Significantly reduced pSMAD2 levels in activin
deficient adipocytes. GAPDH was used as a loading control. (B) quantitation
of pSMAD2 (p*=0.012) normalized to SMAD2 from (A). (C) quantitation of
Smad2 and Smad3 mRNA from differentiating, activin-deficient MEFs. (p** ≤
0.005)The data are presented as ratios of activin-deficient MEFs mRNA levels
to WT set at 1 (solid, horizontal bar). Whisker box plots with boxes
representing the middle 50% of observations and whisker bars representing
the maximum and minimum values. Diff; Differentiation.
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phosphorylation of SMAD2 has been demonstrated, but it remains unclear whether activin
also regulates SMAD3 phosphorylation in adipocytes. Accordingly, we examined the phosphorylation of SMAD2 and SMAD3 using MEFs isolated from activin double knockout
(DKO) mice with global knockout of activin A (Inhba-/-) and activin B (Inhbb-/-). The activin
DKO MEFs were differentiated into adipocytes and the SMAD2 and SMAD3 phosphorylation status was examined on day 8. Activin DKO adipocytes exhibited significantly
less SMAD2 phosphorylation than WT but showed no change in the phosphorylation of
SMAD3 (Figure 4.3 A-B). Like other cell types, activin A treatment of WT preadipocytes
isolated from subcutaneous fat robustly induced SMAD2 and SMAD3 phosphorylation
(data not shown).
Additionally, we assessed MEFs isolated from activin DKO mice for Smad2 and
Smad3 mRNA levels during differentiation. mRNA levels of Smad2 and Smad3 trended
higher at days 5 and 8 relative to WT, with a significantly higher level of Smad3 on day 5
(Figure 4.3 C). These data suggest that in addition to the effects of MEF differentiation on
Smad2 and Smad3 mRNA levels, activins may also play a role.

4.2.3

Subcutaneous and Visceral Preadipocytes Differ in Adipogenic Efficiency
Influenced by Activin Signaling

Activin A inhibits differentiation of 3T3-L1 cells and human-adipocyte progenitors (Hirai
et al., 2005; Zaragosi et al., 2010; Aykul et al., 2020); however, whether depot-selective effects
of activins on adipogenesis occur in preadipocytes is unknown. Thus, we examined the
adipogenic efficiency of primary preadipocytes isolated from subcutaneous and visceral
WAT, and the depot-selective effects of activin A and its inhibitors. Subcutaneous and
visceral preadipocytes from WT mice were induced to differentiate with or without activin
A, activin receptor inhibitor, SB431542, or SMAD3-specific inhibitor, SIS3 (Jinnin, Ihn, and
Tamaki, 2006). We assessed differentiation by BODIPY and Oil Red O staining on day 8 of
differentiation. While differentiation efficiency was approximately 90% in preadipocytes
isolated from the subcutaneous depot (Figure 4.4 A-B0 ), preadipocytes from the visceral
depot differentiated poorly, exhibiting 20-30% differentiation efficiency (Figure 4.5 A-B0 ).
Activin A treatment reduced the differentiation efficiency of subcutaneous preadipocytes,
and activin A-treated visceral preadipocytes differentiated less efficiently than untreated
controls, as very few cells with multilocular lipid droplets were observed (Figure 4.44.5). Although it is clear that activin A treatment in primary subcutaneous preadipocytes
diminished differentiation, this was not as clear in visceral preadipocytes, and was more
challenging to interpret the magnitude of the effect in the context of a cell population that
already differentiated poorly at baseline.
In contrast to activin A, the activin-like kinase (ALK) inhibitor SB431542, that blocks
type I activin receptors (ALK4, ALK7) and type I TGF-β receptor (ALK5), promoted lipid
accumulation in cells derived from both depots, although less so in cells from the visceral
depot. However, treatment with SB431542 greatly enhanced the differentiation of visceral
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Figure 4.4: Activin A, SB431542 and SIS3 Regulate Differentiation of
Subcutaneous Preadipocytes. (A) BODIPY staining on day 8 of
differentiation (green, counterstained with DAPI (blue)), (B) Oil Red O and
(B0 ) Oil Red O, full well view. Activin A (40ng/mL) showing reduced
adipocyte differentiation, while SB431542 (5µM) enhanced differentiation.
SIS3 (3µM) reduced differentiation. Scale bar 400µm. (C) mRNA levels of
adipogenic markers Cebpα, Plin, Leptin and Pparγ on day 8 (*p < 0.05, **p <
0.005).
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Figure 4.5: Activin A, SB431542 and SIS3 Regulate Differentiation of
Visceral Preadipocytes. (A) BODIPY staining (green counter stained with
DAPI blue), (B) Oil Red O and (B’) Oil Red O staining on day 8 of
differentiation. Activin A (40ng/mL) treated cells failed to differentiate
while SB431542 (5µM) markedly induced differentiation. SIS3 (3µM)
treatment had no impact on differentiation. Scale bar 400µm. (C) mRNA
levels of Cebpα, Plin, Leptin, Pparγ on day 8 for the indicated treatments (*p
<0.05, **p < 0.005).
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cells at the cellular and molecular level, with a less robust effect in subcutaneous cells,
which already achieved 90% differentiation efficiency at baseline. In contrast, SMAD3
inhibitor, SIS3, reduced differentiation of subcutaneous, but not visceral preadipocytes
(Figure 4.5 A-B0 ). Thus, SMAD3 inhibitor showed a robust inhibitory effect in subcutaneous
preadipocytes at the cellular and molecular level, but not as clearly in visceral, although
the relatively poor differentiation of visceral cells again makes interpretation challenging.
Overall, these data suggest that subcutaneous and visceral preadipocytes differ in their
differentiation potential and respond differently to processes that impact activin signaling
during adipogenesis.
To further assess the impact of activin A signaling on adipogenesis, we examined the
expression of adipocyte-specific markers in fully differentiated subcutaneous preadipocytes
receiving activin A, SB431542 or SIS3 (Figure 4.4 C). Activin A treated cells showed reduced
expression of adipogenesis and mature adipocyte markers, Cebpα, Perilipin, Leptin and
Pparγ, in keeping with the reduced differentiation observed microscopically. In contrast,
SB431542 did not impact Cebpα, Pparγ and Leptin, but Perilipin, a lipid droplet marker, was
significantly increased. Blocking SMAD3 with SIS3 reduced Cebpα, Pparγ and Perilipin, but
not Leptin. These findings are consistent with roles for activin signaling during adipogenesis,
impacting the expression of key adipogenic regulators.
For visceral preadipocytes, activin A treatment modestly increased the expression of
Cebpα relative to control cells, while Perilipin expression was significantly reduced (Figure
4.5 C). Leptin and Pparγ expression did not change. Activin receptor inhibitor, SB431542,
markedly increased Cebpα, Perilipin, Leptin and Pparγ transcript levels, while SMAD3 inhibitor, SIS3, did not significantly impact mRNA levels. Collectively, these findings suggest
that subcutaneous and visceral preadipocytes may differ in their responses to activin signaling during adipogenesis with much higher differentiation capacity in subcutaneous
preadipocytes. Further, activin signaling and its downstream effector, SMAD3, may contribute to preadipocyte differentiation in primary culture cells, impacting the expression of
key adipogenic regulators.

4.2.4

Adipose-Selective Deletion of Smad2 or Smad3 Have Different Effects on
Weight Gain Under High-Fat Diet Conditions

Smad2 global knockout mice die in utero, while Smad3 knockout mice are smaller at weaning
(Nomura and E. Li, 1998; Waldrip et al., 1998; Weinstein et al., 1998; Y. Zhu et al., 1998;
Datto et al., 1999; Yang et al., 1999). Ubiquitous knockout of Smad3 protects mice from
diet-induced obesity (Datto et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani
et al., 2011; Yadav, Quijano, et al., 2011). However, it is plausible that loss of Smad3 in
non-adipose tissues contributes to this phenotype. To explore the adipose-selective effects
of Smad2 and Smad3, we generated Smad2, Smad3 and Smad2/3 conditional knockout mice
(hereafter, Smad2cKO and Smad3cKO, respectively) using Adiponectin-Cre (Figure 4.6 A-B).
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Figure 4.6: Generation of Smad2cKO and Smad3cKO Mice Using
Adiponectin-Cre. (A) Deletion strategy for Smad2 and (B) Smad3. (C-D)
western blot showing efficiency of Adiponectin-Cre for Smad2 and Smad3,
respectively (E) Quantitation of SMAD2 protein and (F) Quantitation of
SMAD3 protein normalized to GAPDH in both visceral and subcutaneous
WAT.
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Adiponectin-Cre-mediated reduction of SMAD2 and SMAD3 was confirmed by western blot
(Figure 4.6 C-F).
In contrast to the global knockout, adipose tissue-selective reduction of Smad2 or
Smad3, did not result in obvious growth defects under regular diet conditions, and the
mice were viable and fertile. Next, we examined the effects under HFD conditions. Control mice normally remain lean on regular diet, while HFD induces obesity over time.
Adipose-selective Smad2 deletion did not have a significant effect on body weight in males,
irrespective of diet, while Smad2cKO females tended to be slightly heavier than control
mice on HFD at 23 weeks, but no difference was observed on LFD (Figure 4.7 A-B). In
contrast, Smad3cKO male mice on HFD displayed divergence in body weight at 8 weeks and
continued with lower body weights relative to diet-matched controls until the end of the
experiment at 23 weeks. However, the body weight differences did not reach significance
(Figure 4.7 C). Smad3cKO female mice displayed no differences in body weight or size
relative to control littermates (Figure 4.7 D). Since body weight differences in males were
only observed under HFD conditions, we next examined the impact of HFD on SMAD3
expression and phosphorylation in WAT.
Smad3 f lox/ f lox control mice were fed LFD or HFD for 8 weeks or 23 weeks. Visceral
and subcutaneous fat depots were examined for pSMAD3 and SMAD3 protein levels by
western blot. After 8 weeks on diet, normalized protein levels of pSMAD3 were higher in
visceral and subcutaneous WAT depots from HFD fed mice relative to LFD, and at 23 weeks
approximated 8-week LFD levels (Figure 4.8 A-B, A0 -B0 )). Subcutaneous WAT SMAD3
levels were higher on HFD at 8 weeks and 23 weeks relative to LFD fed mice; however,
no changes were observed in SMAD3 levels in visceral WAT. This suggests that SMAD3
protein levels are influenced by diet in an adipose depot-selective fashion.
Smad3cKO mice showed similar fasting blood glucose levels and after glucose injection, we observed slightly lower blood glucose levels in Smad3cKO male mice on HFD
relative to control littermates, which was consistent at each time point of glucose tolerance
testing (GTT), but the differences were not significant (Figure 4.9 A). Female Smad3cKO
mice on HFD showed modestly higher blood glucose levels relative to controls at 15 minutes
and 30 minutes but showed no difference at 90 minutes (Figure 4.9 B).
Smad2cKO mice displayed no significant differences from controls throughout the
GTT experiment, irrespective of sex and diet conditions (Figure 4.10 A-B). Also, there were
no differences in whole body fat mass, lean mass or water composition between controls
and Smad2cKO mice, irrespective of diet or sex (Figure 4.10 C-J).

4.2.5

Smad3-Deficient Male Mice Exhibit Differences in Weight Gain and Subcutaneous Fat Mass

Others have shown reduced body weight in Smad3 global knockout mice, corresponding to
reduced visceral and subcutaneous fat mass (C. K. Tan, Leuenberger, et al., 2011; Tsurutani
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Figure 4.7: Adipocyte-Selective Deletion of Smad3 in Males Results in
Lower Body Weight. (A) Growth curves showing no detectable differences
in the body weights of Smad2cKO male mice relative to control mice fed
HFD or LFD (B) Trend of greater body weights in Smad2cKO females on
HFD (C) Smad3cKO male mice exhibited lower body weight on HFD
compared to controls (D) No difference in body weight in Smad3cKO female
mice on either diet relative to age-matched control. n=8-11.
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Figure 4.8: Phosphorylation of SMAD3 on LFD or HFD for 8 or 23 weeks.
(A-B) Control mice (Smad3f f lox/ f lox ) on LFD or HFD for 8 weeks or 23 weeks.
At 8 weeks, GAPDH normalized protein levels of pSMAD3 were higher in
visceral and subcutaneous depot from HFD fed mice relative to LFD. At 23
weeks pSMAD3 approximated 8-week LFD levels (upper band).
Subcutaneous SMAD3 levels were higher on HFD at 8 weeks and 23 weeks
relative to LFD in subcutaneous adipose depot. (A’-B’) Quantitation of
pSMAD3 from visceral and subcutaneous depot respectively.

Figure 4.9: Glucose Tolerance Test. (A-B) GTT of (Smad3f f lox/ f lox ) control
and Smad3cKO mice on LFD and HFD.

48

Chapter 4. SMAD2/3 Differentially Regulate Adiposity and the Growth of
Subcutaneous White Adipose Tissue

Figure 4.10: Smad2cKO Mice Show Similar Blood Glucose Levels and no
Effect on Fat Mass. (A-B) GTT of Smad2cKO male and female mice. Echo
MRI scan indicating no change in (C) fat mass, (D) lean mass, (E) water, (F)
daily food intake in male and (G) fat mass, (H) lean mass, (I) water, (J) daily
food intake in female.
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et al., 2011; Yadav, Quijano, et al., 2011). To determine if the differences in body weight
between Smad3cKO and control mice were due to the differences in adipose tissue mass,
we measured fat and lean mass by EchoMRI. Smad3cKO male mice exhibited significantly
lower fat mass relative to controls on both LFD and HFD with slight increase in lean mass
and water composition (Figure 4.11 A-C). In contrast, no differences were observed in fat
mass, lean mass, water composition or water and food intake when comparing Smad3cKO
and control female mice (Figure 4.12 A-D).
The differences in total body fat mass were also observed in the subcutaneous fat
depots. Smad3cKO male mice showed significantly lower subcutaneous fat mass under
LFD and HFD conditions. Visceral fat mass was lower in Smad3cKO mice on LFD, while
Smad3cKO mice on HFD showed no difference in their visceral fat mass (Figure 4.11 DE). Smad3cKO mice showed a modest increase in HFD food intake that did not reach
significance (Figure 4.11 F). The differences in subcutaneous fat mass were also reflected by
adipocyte size. Subcutaneous WAT of Smad3cKO mice contained smaller, multiloculated
adipocytes, irrespective of diet. In contrast, visceral WAT did not show clear differences in
adipocyte size under either diet condition (Figure 4.11 G). Overall, these data are consistent
with the lower body weight of Smad3cKO on HFD being attributable at least in part to the
reduction in subcutaneous WAT mass.
Because of the depot-selective effects of Smad3 deficiency we further examined the
mRNA levels of adipogenic markers in subcutaneous WAT from Smad3cKO mice. Under
LFD conditions, all adipogenic markers, Cebpα, Cebpβ, Cebpδ, and Pparγ, trended lower
than controls but with HFD these markers all increased relative to controls and relative
to levels under LFD conditions, suggesting a possible higher sensitivity of Smad3cKO
mice to HFD-related adipogenic effects (Figure 4.13 A-B). We further examined the mRNA
level of genes involved in lipogenesis and lipolysis on both diets in subcutaneous WAT
from Smad3cKO mice and control mice. Subtle differences were observed for several genes
involved in lipogenesis and lipolysis on LFD and HFD. On HFD diet conditions, Acaca,
Scd1, Hsl and Perilipin were slightly higher and lower expression of Fasn, Srebp1, Cd36 and
Atgl in Smad3cKO mice, none of these markers reached significance. (Figure 4.13 C-D).

4.3

Discussion

We have demonstrated that SMAD2 and SMAD3 are not functionally interchangeable
within the context of adipose tissue development, and SMAD3 likely plays the predominant
role in subcutaneous white adipose tissue development and maintenance. Through their
interactions with the ‘common SMAD’ (SMAD4), SMAD2 and SMAD3 are the main downstream transcriptional mediators of the activin signaling pathway (Zaragosi et al., 2010;
Zamani and Chester W. Brown, 2011; M. J. Lee, 2018). Each protein, however, has acquired
non-redundant functions. Smad2 global knockout mice die in utero because of gastrulation
defects, while Smad3 global knockout mice are viable, demonstrating, as in other contexts,
that the SMAD2 and SMAD3 proteins are not completely functionally interchangeable
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Figure 4.11: Adipocyte-Selective Deletion of Smad3 in Males Diminishes
Subcutaneous WAT Irrespective of Diet. (A) Echo-MRI showing lower
percent fat mass in Smad3cKO male mice than control mice fed LFD or HFD
for 21 weeks. (B) No significant change in lean mass or (C) % water
composition. (D) Modest reduction in visceral fat mass on LFD. (E)
Smad3cKO male mice displayed significantly lower subcutaneous fat mass
on both LFD and HFD-fed (F) Daily food intake at 16 weeks. Smad3cKO
male mice on LFD had slight increase in food intake while on HFD both
groups had similar caloric intake (p=0.054). (G) H& E staining of visceral
and subcutaneous adipose tissues at 23 weeks, showing smaller adipocytes
in subcutaneous adipose on LFD and HFD (n=4) while similar adipocyte
sizes in visceral depots of Smad3cKO mice compared to control. Scale bar
400uM.
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Figure 4.12: Smad3cKO Female Show No Effect on Fat Mass. Echo-MRI
scan performed at 21week LFD and HFD fed mice indicating (A) no change
in fat mass, (B) lean mass, (C) water composition and (D) daily food intake
measured manually.

Figure 4.13: mRNA Levels of Adipogenic Markers in Subcutaneous WAT.
(A-B) RT-PCR showing mRNA levels of adipogenic markers (C-D) mRNA
levels of lipogenic and lipolytic markers of control and Smad3cKO mice
(n=4-5) on LFD and HFD fed for 23 weeks relative to the control value of
one. Student’s T-test was applied with p value ≤ 0.05 considered as
statistically significant for each experiment.
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(Nomura and E. Li, 1998; Waldrip et al., 1998; Weinstein et al., 1998; Y. Zhu et al., 1998; Datto
et al., 1999; Heyer et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al., 2011;
Yadav, Quijano, et al., 2011; Yadav and Rane, 2012; Yadav, Devalaraja, et al., 2017; J. H. Lee
et al., 2020).
Previous studies have shown that Smad3 is required for the normal development
of adipose tissue and normal somatic growth, as Smad3 global KO mice are small, have
reduced adiposity and show protection from diet-induced obesity (Nomura and E. Li, 1998;
Y. Zhu et al., 1998; Datto et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani et al.,
2011; Yadav, Quijano, et al., 2011). However, this could be a secondary consequence of
physiological effects from other tissues such as skeletal muscle, liver or pancreas (Y. Zhu
et al., 1998; Datto et al., 1999; Yang et al., 1999; C. K. Tan, Leuenberger, et al., 2011; Tsurutani
et al., 2011; Yadav, Quijano, et al., 2011; Yadav and Rane, 2012; Yadav, Devalaraja, et al.,
2017; M. J. Lee, 2018; J. H. Lee et al., 2020). Therefore, we examined the tissue-selective
effects of Smad2 and Smad3 on adiposity and diet-induced obesity.
Activin A promotes proliferation and inhibits differentiation via SMAD2 phosphorylation in 3T3-L1 preadipocytes and human adipocyte progenitors (Hirai et al., 2005; Zaragosi
et al., 2010). To examine whether activins signal through both SMAD2 and SMAD3 phosphorylation during adipogenesis, we differentiated MEFs derived from activin-deficient
mice (activin DKO) and surprisingly found significantly reduced levels of pSMAD2 but not
pSMAD3. The reason that pSMAD3 levels remained unchanged in the absence of activins
is unclear but could be due to maintenance of expression through the effects of other TGF-β
family ligands or due to a yet to be defined adipose-selective role for pSMAD2 that does
not require pSMAD3 (Bonomi et al., 2012).
Signal transduction by several TGF-β family members regulates adipogenesis in vivo
and in vitro, including activins/SMADs (Choy, Skillington, and Derynck, 2000; Hirai et al.,
2005; L. Li et al., 2009; Zaragosi et al., 2010; Zamani and Chester W. Brown, 2011; M. J. Lee,
2018; Aykul et al., 2020). However, depot-selective effects of activin on adipogenesis in
preadipocytes have not been studied previously. Therefore, we differentiated preadipocytes
isolated from different depots in the presence of exogenous activins. Herein, we examined
the effect of activin/SMAD signaling on preadipocyte differentiation in visceral and subcutaneous WAT, revealing that subcutaneous and visceral preadipocytes respond differently
and display different properties during adipogenesis with much higher differentiation
efficiency in subcutaneous relative to visceral preadipocytes (Figures 4.4-4.5). There was
higher lipid content in cells from the subcutaneous depot, while visceral preadipocytes
produced fewer differentiation foci. Collectively, we show that activin A negatively impacts
differentiation, whereas blocking activin signaling with SB431542 augments the differentiation of subcutaneous and visceral preadipocytes as shown by others in 3T3-L1 cells and
human primary subcutaneous preadipocytes (Zaragosi et al., 2010; Merrick et al., 2019;
Aykul et al., 2020). Since SB431542 blockade is not specific to activin signaling, inhibiting
three of the type I TGF-β family receptors, ALK4, ALK5 and ALK7, we cannot exclude
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the possibility that other ligands such as TGF-β might also be impacted, although ALK4
and ALK7 are the type I receptors for activins, and ALK7 is the predominant type I activin
receptor in adipocytes (Carlsson et al., 2009).
SMAD2 showed sustained expression in vivo and during adipocyte differentiation in
vitro, while SMAD3 expression declined as adipocyte differentiation progressed in vitro and
as adipose tissue growth progressed in both visceral and subcutaneous fat. This difference
in temporal expression might suggest that SMAD3 plays a more critical role during early
stages of preadipocyte specification and differentiation, whereas SMAD2 may play an
overlapping or distinct role(s) at early stages and also important roles at later stages in
mature adipocyte function and maintenance. It is clear that activin A treatment in primary
subcutaneous preadipocytes diminishes differentiation. This is not as clear in visceral
preadipocytes, but it is more challenging to interpret in the context of a cell population that
already differentiates poorly at baseline. Similarly, the SMAD3 inhibitor showed a robust
inhibitory effect in subcutaneous preadipocytes at the cellular and molecular levels, but
not as clearly in visceral, although the relatively poor differentiation of visceral cells again
makes interpretation challenging. Conversely, treatment with SB431542 greatly enhanced
the differentiation of visceral cells at the cellular and molecular level, with a less robust
effect in subcutaneous cells, which already achieve 90% differentiation efficiency at baseline.
Thus, activin A and SMAD3 inhibition have similar effects in vitro, diminishing adipocyte
differentiation, whereas SB431542, an inhibitor of 3 different type I receptors, enhances
adipocyte differentiation. The similar effects of activin A and a SMAD3 inhibitor are
counterintuitive, since SMAD3 is a downstream mediator of activin signaling. However,
SMAD2 can also function in this capacity, so the result does not support a simple model of
SMAD3-selective activin signaling. Unfortunately, to our knowledge, a specific SMAD2
inhibitor is not commercially available and additional experiments will be required to
reconcile these observations. Irrespective, evidence for depot-selective effects for SMAD3 is
most strongly provided by the in vivo experiments, showing disproportionate reduction of
fat mass and cell size in subcutaneous WAT. Differences between the effects of SMAD2 and
SMAD3 are best illustrated by no significant impact on weight gain in the Smad2cKO mice.
Using Smad2cKO and Smad3cKO, we have shown that adipose tissue-selective reduction of Smad2 or Smad3 using Adiponectin-Cre had different effects on diet-induced weight
gain. Body weight and fat mass of Smad2cKO male and female mice were not different from
control littermates. This suggests that Smad2 plays little to no role in maintaining adipose
tissue during mid to late adipogenesis in vivo. In contrast, Smad3cKO mice demonstrated
a sex-dependent effect on weight gain. Smad3cKO male mice gained less weight relative
to control littermates on HFD, while females were similar to control mice, indicating a
sex-influenced role for Smad3 on adiposity. The phenotypic differences between the adiposeselective Smad3cKO and the Smad3 global KO model reported by others (including no
report of sexual dimorphism) may be due to secondary physiological effects that occur in
the global knockout, the more restricted perturbation of expression in the Smad3cKO, or
differences in the timing of SMAD3 reduction in the two models.
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Figure 4.14: Working Model Showing Effects of SMAD2 and SMAD3 on
White Adipose Tissue. SMAD2 and SMAD3 expressed in preadipocytes are
phosphorylated by Activin A and thereby inhibit adipocyte differentiation
by suppressing Pparγ and Cebpα. Adipocyte-selective, Adipoq-Cre-mediated
deletion of Smad2 does not impact white adipose tissue (WAT) development
or diet-induced obesity, while adipocyte-selective deletion of Smad3
diminishes the subcutaneous (but not visceral) white adipose tissue mass in
male.

Smad3cKO male mice exhibited decreased adiposity on HFD with less subcutaneous
fat and no difference in visceral fat relative to controls. Lean mass increased slightly on
both diets and water composition did not differ, nor did food intake. These findings are
consistent with the lower body weight of Smad3cKO male mice on HFD being due at
least in part to the reduced accumulation of subcutaneous WAT mass. The reason for the
predominant effect in subcutaneous fat is unclear but may be due to intrinsic differences
between the depots in their requirements for SMAD3-mediated signaling or differences in
Adiponectin-promoter-driven Cre expression in visceral and subcutaneous fat depots. This
notion is consistent with an earlier report that the Adiponectin promoter is active during fetal
subcutaneous adipose tissue development but postnatally in the visceral depot (M. Shao
et al., 2017). In summary, our findings indicate that adipose-selective Smad3 but not Smad2
deficiency results in significantly lower subcutaneous WAT mass, suggesting an important
selective role of SMAD3 in subcutaneous WAT development in vivo (Figure 4.14).
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One potential limitation of this study is our decision to use the Adiponectin-Cre mouse.
For the purpose of achieving adipose-selective gene inactivation, and for studying events
that occur in the middle to late stages of adipogenesis and in mature adipocytes, it has
been informative. However, it is plausible that SMAD-mediated events occurring at earlier
stages of adipogenesis have not been substantially impacted in our model. Thus, to fully
understand the role of SMAD-mediated signaling and associated molecular mechanisms
that occur during earlier stages, additional studies are needed using alternative strategies.
This will allow us to investigate specific deletion of SMAD2 and SMAD3 individually or
in combination at specific time points to better understand the complex interrelationship
between SMAD2, SMAD3, adipocyte development and function.
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Chapter 5
Combinatorial Role of SMAD2/3 on Adiposity

5.1

Introduction

SMAD2 and SMAD3 are almost structurally identical downstream transduction signals
of TGF-β/activin signaling. As discussed in chapter 2 and 3, depending on the cellular
context, these two transcription factors may have similar, unique, or overlapping roles
depending on which SMAD complex is present in each tissue (Y. Shi and J. Massagué, 2003;
Q. Li, Pangas, et al., 2008; Kriseman et al., 2019; Kroon et al., 2017; S. Huang, Chen, Su, et al.,
2019; S. Huang, Chen, Humeres, et al., 2020). In the previous chapter, we studied the effect
of adipose selective single knockout of Smad2 and Smad3 on adipose tissue function and
observed that Smad3 knockout partially protected the male mice from diet-induced obesity
(DIO) while female cKO mice showed no effect on diet-induced obesity. Smad2 showed
little to no role on adipose tissue during mid to late stages of adipogenesis. This suggested
that SMAD2 and SMAD3 have at least some distinct roles in adipose tissue. However,
we do not fully understand the combinatorial requirement of SMAD2/3 in adipose tissue
development and function. Herein, we discuss the impact of combined adipose selective
deletion of Smad2/3 during mid to late adipogenesis.

5.2
5.2.1

Results
Adipose-Selective Deletion of Smad2/3 Protects Mice from Diet-Induced
Obesity in a Sex-Specific Manner

To explore the adipose-selective combined effects of SMAD2/3, we generated Smad2/3 double conditional knockout mice (hereafter, Smad2/3cKO) using Adiponectin-Cre and deletion
was confirmed by western blot (Figure 5.1). Adiponectin-Cre-mediated reduction of SMAD2
and SMAD3 was confirmed by RT-PCR and western blot. First, we investigated whether
the adipose tissue-selective reduction of Smad2/3 results in any survival or growth defect.
Smad2/3cKO mice did not show any obvious growth defects under regular diet conditions
(Envigo Lab Diet 7912), and the mice were healthy and fertile. Next, we examined the effects
of Smad2/3 under HFD and LFD conditions. Smad2/3 f lox/ f lox (control) and Smad2/3cKO mice
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Figure 5.1: Generation of Smad2/3cKO Mice Using Adiponectin-Cre.
Western blot showing efficiency of Adiponectin-Cre for Smad2/3 in both
visceral and subcutaneous WAT.

Figure 5.2: Lower Body Weight in Smad2/3cKO Mice in Females. Growth
curves showing (A) no detectable differences in the body weights of
Smad2/3cKO male mice relative to control mice fed HFD and LFD, n= 6-8, (B)
lower body weight in Smad2/3cKO females on HFD compared to controls,
n=6-8.
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were fed LFD or HFD for 22 weeks starting from the age of 5 weeks. As predicted, these
mice normally remained lean on LFD diet, while HFD resulted in diet-induced obesity (DIO)
over time. Surprisingly, in contrast to the earlier observed phenotype for Smad3cKO male
mice, adipose-selective Smad2/3 deletion did not show any effect on body weight in males.
In contrast to males, however Smad2/3cKO female mice on HFD displayed divergence in
body weight starting at 6 weeks and continued with lower body weight gain relative to
diet-matched controls with significant difference in body weight at weeks 13, 14 and 17 and
continued to show this divergence beyond 20 weeks (Figure 5.2 A-B). This demonstrates
that Smad2/3cKO female mice on HFD exhibit partial protection from DIO.

5.2.2

Smad2/3-Deficient Female Mice Exhibit Differences in Fat Mass along
with Weight Gain

To determine if the differences in body weight between Smad2/3cKO and control female
mice on HFD were due to the differences in adipose tissue mass, we measured fat and lean
mass by EchoMRI. In the beginning when both diets were started, Smad2/3cKO female
mice had same fat mass as control littermates. However as the mice continued with HFD,
Smad2/3cKO female mice exhibited lower fat mass relative to controls on HFD with slight
increase in lean mass and water composition at 16 weeks and 22 weeks on HFD compared
to control littermates (Figure 5.3 A-I). In contrast, no differences were observed in fat mass,
lean mass, and water composition when comparing Smad2/3cKO and control male mice in
the beginning at 5 weeks or at 16 weeks till the time of tissue harvest at 22 weeks. (Figure
5.4 A-J).
Normally, DIO results in glucose intolerance. To determine whether this was the case
in Smad2/3cKO female mice, we measured blood glucose levels at baseline and after glucose
injection. Smad2/3cKO mice showed similar fasting blood glucose levels as controls at
baseline and after glucose injection, lower blood glucose levels were consistantly observed
in Smad2/3cKO female mice on HFD at initial 60 minutes and then merged at 90 minutes.
No difference was detected in blood glucose levels under LFD conditions (Figure 5.5 A-C).
Two-way (mixed model) ANOVA followed by post hoc test were used to evaluate statistical
significance. To determine whether the improvement in blood glucose levels in Smad2/3cKO
mice was due to improved insulin sensitivity, insulin tolerance testing (ITT) was performed
in females. Smad2/3cKO mice did not show any differences in blood glucose levels relative
to controls after insulin injection (Figure 5.5 D).
To determine the effect of Smad2/3 deletion on adipose tissue in females, visceral and
subcutaneous WAT were also dissected from Smad2/3cKO and control mice on both diets.
Consistent with the reduction in fat mass in Smad2/3cKO female on HFD, Smad2/3cKO
female mice showed lower visceral and subcutaneous fat mass under HFD conditions
relative to LFD or HFD control littermates, however the decrease in fat mass from both
the depots did not reach statistical significance (visceral, p=0.053) (Figure 5.5 E). Taken
together these results suggest that Smad2/3cKO mice have reduced adiposity on HFD. The
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Figure 5.3: Lower Percent Fat Mass in Smad2/3cKO Mice in Females.
Echo-MRI showing (A-C) fat mass, lean mass, and water composition at 5
weeks, (D-F) 16 weeks and (G-I) 22 weeks of Smad2/3cKO female mice and
control mice, n=6-8.
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Figure 5.4: Adipocyte-Selective Deletion of Smad2/3 in Males Exhibits
no Change in Fat Mass. Echo-MRI showing (A-C) fat mass, lean mass and
water composition at 5 weeks, (D-F) 16 weeks and (G-I) 22 weeks of
Smad2/3cKO male mice and control mice, n=6-8. (J) No detectable change in
fasting blood glucose level in GTT.
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Figure 5.5: Diminished Visceral and Subcutaneous WAT in Smad2/3cKO
Mice on HFD. Glucose tolerance test (GTT) showing (A-B) baseline blood
glucose and after injection (C) area under the curve (AUC). (D) Insulin
tolerance test (ITT). (E) Reduction in visceral (0.053) and subcutaneous fat
mass on HFD but not significant. (F) H & E staining of visceral and
subcutaneous adipose tissues at 22 weeks of Smad2/3cKO relative to control
female mice on LFD and HFD (n=4). Scale bar 400uM. (G) H & E staining of
liver of Smad2/3cKO females. (H) Daily food intake on HFD.
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differences in visceral fat mass were also reflected by adipocyte size. Visceral WAT of
Smad2/3cKO female mice on HFD contained relatively small multiloculated adipocytes. In
contrast, subcutaneous WAT did not show clear differences in adipocyte size under either
diet condition (Figure 5.5 F).
Often, DIO results in hepatic steatosis due to ectopic fat deposition in liver. Therefore,
we analyzed the effect of Smad2/3 deletion on hepatic steatosis by H& E staining. HFD,
control mice showed prominent hepatic steatosis (white fat patches). Loss of SMAD2/3 in
adipose tissue, however, resulted in protection from diet-induced hepatic steatosis (Figure
5.5 G). To determine if lower body weight in Smad2/3cKO mice is due to lower caloric intake,
we measured food intake. Smad2/3cKO mice showed a modest increase in HFD food intake
that did not reach significance (Figure 5.5 H). Overall, these data are consistent with the
lower body weight of Smad2/3cKO female mice on HFD being attributable at least in part to
the reduction in total WAT mass, including visceral and subcutaneous, and reduction of
Smad2/3 in adipose results in indirect effects on hepatic lipid metabolism or storage.

5.2.3

Smad2/3cKO Mice Show Increased Energy Expenditure

Despite modest increase in food intake, Smad2/3cKO female mice on HFD showed lower
body weight and reduced adiposity. This finding prompted us to investigate energy
expenditure, substrate utilization and activity in Smad2/3cKO female mice. We performed
24 hour indirect calorimetry for seven days. All metabolic parameters were measured in
22-week-old mice under fed and fasted conditions. Data is presented as an average of all
days (left panel) and average at every indicated time points per mouse (right panel), n=6.
Values normalized to body weight during both the light and dark cycle. Smad2/3cKO mice
showed greater oxygen consumption (VO2 ), carbon dioxide production (VCO2 ), and total
energy expenditure (TEE), indicative of higher metabolic rates (Figure 5.6 (A-A0 )-(C-C0 )).
The differences in VO2 , VCO2 , and energy expenditure persisted in light and dark cycles
while no effect of genotype was observed on physical activity (Figure 5.6 D-D0 )).
We further determined if there were any differences in substrate utilization. Smad2/3cKO mice showed higher respiratory exchange ratio (RER) (0.75) compared to controls
(0.70) indicating that Smad2/3cKO mice use higher carbohydrate as an energy source than
control mice (Figure 5.6 E-E0 ). Therefore, differences in energy substrate utilization may
be contributing to the reduced adiposity in Smad2/3cKO mice. Considering the difference
in body weight and fat mass, it is plausible that reduced adiposity in Smad2/3 conditional
knockout mice is due to higher oxygen consumption and total energy expenditure.
Collectively, these results suggest that Smad2/3 deletion improves metabolic rate of
female mice. We also looked at these metabolic parameters under fasting conditions, and
found the same results. Smad2/3cKO mice showed greater VO2 , VCO2 and total energy
expenditure. However, all three parameters declined as these mice continued to fast.
Activity level increased for first few hours then declined. No difference was observed in the
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Figure 5.6: Indirect Calorimetry Showing Higher Metabolic Rate in
Smad2/3cKO Mice on HFD. (A-A0 ) O2 consumption rate (VO2 ), (B-B0 )
carbon dioxide production (VCO2 ), (C-C0 ) total energy expenditure (TEE),
(D-D0 ), total activity and (E-E0 ) respiratory exchange ratio (RER) of
Smad2/3cKO and control female mice on HFD. Data are expressed as mean
± standard error of the mean (SEM). p value ≤ 0.05 considered as
statistically significant, *p value ≤ 0.05, **p value ≤ 0.005.
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Figure 5.7: Indirect Calorimetry Showing Higher Metabolic Rate in
Smad2/3cKO Mice on HFD in Fasting State. (F-F0 ) O2 consumption rate
(VO2 ), (G-G0 ) carbon dioxide production (VCO2 ), (H-H0 ) total energy
expenditure (TEE), (I-I0 ) total activity and (J-J0 ) respiratory exchange ratio
(RER) of Smad2/3cKO and control female mice on HFD in fasting conditions.
Data is presented as an average of all days (left panel) and average at every
indicated time points per mouse (right panel), n=6. Values normalized to
body weight during both the light and dark cycle. Data are expressed as
mean ± standard error of the mean (SEM). Two-way mixed model ANOVA
were used for multiple comparisons among genotypes overtime) and
student’s T-test was applied with p value ≤ 0.05 considered as statistically
significant for each experiment.
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Figure 5.8: SMAD2/3 Regulate Key Genes Involved in Adipogenesis,
Lipogenesis and Lipolysis. (A-B) mRNA levels of adipogenic markers
Cebpα, Cebpβ, Pparγ, Fabp4, Wnt10b, Pref1, Smad2 and Smad3 (C-D) mRNA
levels of lipogenic and lipolytic markers Acaca, Fasn, Dgat2, Cd36, Plin, Hsl,
Atgl and Scd1 in subcutaneous WAT of control and Smad2/3cKO mice (n=4-5)
on LFD and HFD fed for 22 weeks. Student’s T-test was applied with p
value ≤ 0.05 considered as statistically significant. * p value ≤ 0.05, ** p
value ≤ 0.01

respiratory exchange ratio (RER) in fasting condition (Figure 5.7 (F-F0 ) (G-G0 ) (H-H0 ) (I-I0 )
(J-J0 )).

5.2.4

SMAD2/3 Regulate Key Genes Involved in Adipogenesis, Lipogenesis
and Lipolysis

To further investigate the causes of the reduced fat depot sizes of Smad2/3cKO mice, we examined the mRNA levels of adipogenic, lipogenic and lipolytic markers from subcutaneous
WAT from Smad2/3cKO female mice. Smad2/3cKO mice showed significantly reduced levels
of Smad2 and Smad3 transcripts, as expected, on both LFD and HFD. Under LFD conditions,
adipogenic markers, Cebpα, Cebpβ, Pparγ, and Pref1 were decreased in Smad2/3cKO but did
not reach significance. Conversly Fabp4 and Wnt10b increased but not significantly under
LFD conditions (Figure 5.8 A). In contrast, on HFD conditions, adipogenic markers Cebpα,
Pparγ and Wnt10b decreased significantly, while Cebpβ increased but not significantly. Fabp4
and Pref1 decreased but did not reach significance in Smad2/3cKO mice (Figure 5.8 B).
On HFD, genotype effect was observed for several gene involved in lipogenesis
and lipolysis. Smad2/3cKO females on LFD showed no significant changes in these genes
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Acaca, while Fasn and Perilipin were lower, Dgat2 and Cd36 were slightly higher although
these genes did not reach statistical significance (Figure 5.8 C). On HFD conditions, however, lipogenic and lipolytic markers, Fasn, Dgat2, Cd36, Hsl and Scd1 were significantly
downregulated while we found reduced expression with Acaca, Perilipin and Atgl, but did
not reach significance (Figure 5.8 D). Taken together, these data suggest a possible cellular
mechanism by which adipose selective SMAD2/3 deletion results in the reduced adiposity
of Smad2/3cKO female mice under HFD conditions.

5.3

Discussion

Using adipose selective knockout of Smad2/3, we have shown that adipose tissue-selective
reduction of Smad2/3 using Adiponectin-Cre had sex-selective effects on diet-induced weight
gain. Smad2/3cKO male mice had similar body weight compared to controls irrespective of
diet, while Smad2/3cKO female mice gained less weight on HFD, exhibiting less visceral and
subcutaneous fat mass. Associated with this phenomenon is the downregulation of genes
involved in adipogenesis, lipogenesis and lipolysis, reduced hepatic steatosis and increased
metabolic rate. This demonstrates that SMAD2 and SMAD3 have partially overlapping roles
in adipose tissue development or function such as with adipose selective deletion, (1) Smad2
showed no phenotype, (2) Smad3 showed mild phenotype in males and (3) Smad2/3 showed
strong phenotype in females. We speculate that the differences in outcomes between males
and females may be linked to sex hormone responses and endocrine mediated pathways.
Taken together, this study highlights that sex is an important factor to consider when
assessing phenotypes observed with Smad3 and in Smad2/3 mediated signal transduction.
It is important to acknowledge a potential limitation of this study, which was our
decision to use the Adiponectin-Cre mouse as stated in chapter 4. To achieve adiposeselective gene inactivation, and for studying events that occur in the early to middle stages
of adipogenesis, it will be very informative to use and dissect the role of SMAD2/3 using
Cre expressed at a stages earlier than Adiponectin-Cre during embryogenesis. It is plausible
that SMAD-mediated events occurring at earlier stages of adipogenesis would have been
missed as a consequence of the timing of SMAD2/3 inactivation. Thus, to fully understand
the role of SMAD-mediated signaling and associated molecular mechanisms that occur
during earlier stages, additional studies are needed using alternative strategies with early
Cre expressing in preadipocytes. This may allow us to investigate roles of SMAD2/3
at specific time points to better understand the relationship between SMAD2, SMAD3,
adipocyte development and function. Also, investigating the mechanism by which Smad2/3
play a role in modulating sex selective phenotypes is an important future direction.
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Chapter 6
Role of Activins on Preadipocyte Proliferation,
Differentiation and Cell Fate

6.1

Introduction

Activin signaling is known to regulate cell proliferation in many contexts including adipose
tissue. Adipose tissue specific loss of activin A and B results in severe reduction of adipose
tissue mass suggesting that activins are essential for the specification, differentiation and
maintenance of proper adipose tissue growth (Namwanje and Irudayam et al. in preparation). SMAD-mediated activin signaling regulates cell proliferation. Activin A promotes
proliferation in 3T3-L1 preadipocytes and adipocyte progenitors (Hirai et al., 2005; Zaragosi
et al., 2010). However, the cell autonomous roles of activins on cell proliferation in primary
preadipocytes isolated from visceral and subcutaneous depots had not been assessed. Therefore, we examined the role of activin A, activin receptor inhibitor, SB431542 and SMAD3
specific inhibitor, SIS3 in proliferating preadipocytes isolated from subcutaneous depots.
Additionally, it has been shown that activin A inhibits differentiation via SMAD2 in
3T3-L1 and human adipocyte progenitors (Hirai et al., 2005; Zaragosi et al., 2010). However,
the cell autonomous roles of activins on cell differentiation and cell fate in primary culture
cells had not been assessed. Additionally, in previous studies from our lab, it has been
observed that the loss of activins A and B alters the phenotypic characteristics of white
adipose tissue (WAT) in mice, including smaller adipocytes and histologic features typically
associated with brown adipose tissue (BAT) (Namwanje and Irudayam et al. in preparation).
To determine the effects of activins on adipocyte differentiation, we first determined
the cell autonomous role of activins on adipogenesis and cell fate using mouse embryo
fibroblasts (MEFs). We compared WT and activin A/activin B double knockout (Inhbb-/-,
Inhba-/-). As activin double knockout (here in activin DKO) mice die on postnatal day 1.
Therefore, we developed a cell-based assay by isolating MEFs from WT and activin DKO
embryos at e13.5 and differentiated them in vitro. After getting activin DKO embryos, which
was challenging due to limited numbers of the desired genotype, we did several rounds of
experiments at different times, encompassing four biological replicates of WT and activin
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Figure 6.1: Activin A Promotes Subcutaneous Preadipocyte Proliferation
While Activin Receptor Inhibitor SB431542 Inhibits Proliferation.
Proliferation of preadipocytes in presence or absense of activin A (40ng/mL
or 60ng/mL) (left), activin receptor inhibitor, SB431542 (5µM, 10µM, or
25µM) (middle) and SMAD3-specific inhibitor, SIS3 (3µM, 5µM, 10µM or
20µM)(right) for 48 hrs. Student’s T-test was applied with p value ≤ 0.05
considered as statistically significant for each experiment. *p <0.05, ****p <
0.00005.

DKO. MEF isolation, differentiation, bioenergetics, RNA, and protein analyses were all
performed on all biological replicates.

6.2
6.2.1

Results
Activin A Promotes Proliferation of Preadipocytes

To determine the effect of activin A on preadipocyte proliferation, subcutaneous preadipocytes from wild type mice were treated with or without activin A (40ng/mL or
60ng/mL) (left), activin receptor inhibitor, SB431542(5µM, 10µM, or 25µM) (middle), and
SMAD3-specific inhibitor, SIS3 (3µM, 5µM, 10µM or 20µM) (right) in 10% growth medium
every 24hrs for 2days. Viability was assessed by MTT assay following manufacturer’s
instructions. A dose dependent effect of activin A was observed on proliferation. Activin A
treatment augmented proliferation while SB431542 inhibited proliferation in a dose dependent manner (Figure 6.1 ). SMAD3-specific inhibitor, SIS3 had no effect on cell proliferation
at any concentration. During treatment with activin, SB and SIS3, we did not observe cell
death, assayed using flow cytometry by annexin-V staining (Figure 6.2 ).

Chapter 6. Role of Activins on Preadipocyte Proliferation, Differentiation and
Cell Fate

70

Figure 6.2: Apoptosis Assay. Annexin-V Staining showing no apoptotic
cells in activin A, SB431542 and SIS3-treated preadipocytes, while cells
treated with H2O2 showed very high level of apoptotic cells served as a
positive control.

6.2.2

Activin Deficiency Promotes Adipogenesis in Differentiating MEFs

To determine the consequences of total loss of activin A and activin B on differentiating
activin DKO cells. We examined the expression of adipogenic markers in early and late
stages of differentiation. MEFs were induced with hormonal cocktail and harvested at the
indicated time points (day3,5 and 8). Activin deficiency promoted faster differentiation
of MEFs, as determined by morphological appearance (phase contrast, Oil Red O, BODIPY and DAPI staining) (Figure 6.3 top). This was further demonstrated by adipogenic
marker mRNA expression in the differentiating MEFs (WT vs activin DKO). Interestingly,
the expression of Cebpα, Cebpβ and Pparγ was increased on days 3, 5 and 8 with significant
increases of all 3 genes on day 8. The expression of Cebpδ did not change much at any
time point and Fabp4 was significantly increased on day 3 but did not show significant
differences on days 5 and 8. Preadipocyte specific markers Pref1 and Wnt10b did not change
significantly. Therefore, the combined deficiency of activin A and activin B resulted in
enhanced adipogenesis (Figure 6.3 bottom left). Because of the smaller sizes of adipocytes
observed in activin-deficient mice, we measured glycerol released in the media of differentiated activin DKO and WT MEFs to determine if lipolysis might be a contributing factor. The
results showed a significant increase in glycerol release in activin DKO adipocytes which
further increased in cells treated with (5µM) isoproterenol, however similar effects were
observed in both genotypes (Figure 6.3 bottom right).
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Figure 6.3: Activin Deficiency Promotes Adipocyte Differentiation of
MEFs. Phase contrast, Oil Red O, BODIPY and DAPI staining showing
morphology of WT and activin DKO MEFs differentiated into adipocytes on
day 8 (top). Graph shows the relative gene expression of adipocyte
differentiation markers evaluated by RT-PCR on day 3, 5 and 8 of
differentiation. *p < 0.05; **p < 0.005; ***p < 0.001, (n=3 embryo per
genotype) (Bottom left). Cyclophilin was used as a normalizer. Quantitative
enzymatic determination of glycerol showed a significant level of glycerol
release in activin DKO cell which further increases in the ISO (5uM) treated
cells (Bottom right).
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Activin Deficiency Induces Browning in Differentiating Activin DKO
MEFs

To ascertain the bioenergetic potential of activin deficient MEFs, we examined the brown
adipocyte-specific markers. We first looked at expression by immunofluorescence of the
browning marker, UCP1 in activin DKO and WT differentiated MEFs. Activin DKO cells
demonstrated significantly more UCP1 positive cells than WT (Figure 6.4 top left). Browning markers Ucp1, Cidea, Pgc1α and Prdm16 were examined on days 3, 5 and 8 in the
presence or absence of isoproterenol (Figure 6.4 top right). The qRT-PCR analysis showed
significant upregulation of brown markers, Ucp1 and Cidea as early as day 3 and remained
significantly increased on days 5 and 8, while Pgc1α was significantly increased on days 5
and 8, when most of the cells were mature adipocytes. We did not see changes in Prdm16
(a very early marker of brown adipogenesis) (Figure 6.4 bottom left). Further, addition of
isoproterenol (ISO), had no further effect on gene expression other than a modest, significant
reduction in Prdm16 (Figure 6.4 bottom right).

6.2.4

Enhanced Mitochondrial Gene Expression in Activin-Deficient Differentiated MEFs

We further looked at several browning and other markers involved in mitochondrial biogenesis using antibodies against UCP1, PGC-1α and electron transport chain (ETC) complexes.
We found that UCP1 and PGC-1α were significantly elevated in activin DKO differentiated
MEFs on days 5 and 8 (5-day data not shown) (Figure 6.5 top and bottom). We further
examined the expression of ETC components from complexes I, II, III, IV and V on days
5 and 8. OXPHOS antibody cocktail directed against ETC complex proteins showed a
significantly elevated levels in activin DKO cells on day 5 and 8 (5-day data not shown)
(Figure 6.5 top and bottom). This is yet another indication that cell autonomous effects of
activin deficiency are linked to a bioenergetic profile that is consistent with a "brown-like"
adipocyte phenotype. Increased mitochondrial number and activity in differentiated activin
DKO MEFs has been corroborated by Seahorse and Mitotracker analysis (data not shown,
Namwanje and Irudayam et al. in preparation).
Thus, the expression of UCP1, PGC-1α and ETC complex proteins showed that the
mitochondria of activin DKO cells are more abundant than WT to meet the higher energy
demands of the observed "brown" like cells.
The observed browning in differentiated, "activin-deficient" MEFs prompted us to
investigate whole transcriptional changes. We isolated total RNA from differentiated (day
8) MEFs and performed RNA-seq. This analysis showed 3179 differentially expressed genes
at day 8 of differentiation in activin DKO cells when compared to WT cells (P<0.05, fold
change > 1.5). Among differentially expressed genes, 239 were involved in lipid metabolic
processes (Figure 6.6 circle bar in left).
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Figure 6.4: Activin Deficiency Induces Browning in MEFs.
Immunofluorescence staining for UCP+ cells (top left) and quantitation (*p
< 0.01) (top right) in differentiated MEFs on day 8 isolated from WT and
activin DKO MEFs. RT-PCR showing activin DKO MEF exhibit enhanced
expression of BAT-specific genes (Ucp1, Cidea, Pgc1-α and Prdm16) on days 3,
5 and 8 of differentiation (bottom). 5uM of Isoproterenol treatment shows no
additionally significant effect on BAT specific genes (bottom right). mRNA
fold difference relative to normalizer (Cyclophilin). *p < 0.05; **p < 0.005;
***p < 0.001. * P< 0.05, considered statistically significant relative to wild
type (n=3 embryo per genotype).
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Figure 6.5: Enhanced Mitochondrial Gene Expression in
Activin-Deficient Differentiated MEFs. Western blot analysis of UCP1,
PGC1α and Electron transport chain complex (ETC) indicates increased level
of protein in activin DKO cells relative to WT cells ((top left). Quantitation of
UCP1, ETC protein and PGC1α (top right and bottom). Band intensity
quantitation of UCP1, ETC protein and PGC1α compared to GAPDH in
image J. *p <0.05; **p < 0.005; ***p < 0.001. * P< 0.05, considered
statistically significant relative to wild type (n=3 embryo per genotype).
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Figure 6.6: Activin Deficiency Induces Browning Genes in MEFs.
Differentially expressed genes involved in lipid metabolism (circle bar in
left), heat map of RNA-seq showing signature genes associated with
browning with fold changes (right) and protein-protein interaction map
showing key transcription factors involved in adipogenesis (bottom left).
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Figure 6.7: Differentially Expressed Genes Share Common Ancestral
Lineages. Venn diagram shows differentially expressed genes in activin
DKO differentiated MEFs. These genes share signature involved in the
differentiation of different tissue types.

Additinally, upregulation of browning and mitochondrial gene signatures were
observed, corroborating previous results. Activin-deficient adipocytes exhibited significant
upregulation in transcripts involved in browning, mitochondrial function, and energy
expenditure including Ucp1, Cidea and several others (Figure 6.6 heat map, right). We also
observed enrichment of several transcription factors involved in adipogenesis, including
SMAD3 (Figure 6.6 bottom left).
Thus, total activin loss has resulted in an increase of bioenergetic markers at the
mRNA and protein levels, endorsing that the activin DKO cells are assuming brownlike characteristics at early stages of differentiation. Additionally, hierarchical clustering
revealed a gene signature related to skeletal muscle, osteoblasts, fibroblasts, consistent with
the ancestral link between fat, osteoblasts and skeletal muscle (Figure 6.7 ) and (Figure 2.1)
We further analyzed differentially expressed genes using EnrichR. The KEGG 2019
Mouse Pathways identified several key signaling pathways that are involved in adipose
tissue growth, survival, and energy homeostasis for the differentially expressed genes in
activin DKO differentiated MEFs compared to WT MEFs. Among top signaling pathways,
PI3K-AKT signaling was the first hit among the significantly enriched pathways, a key
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pathway dysregulated in obesity and diabetes (X. Huang et al., 2018) (Table 6.1).
Table 6.1: KEGG 2019 Mouse Pathways Analysis.
Name

P-value

Adjusted
P-value

Odds
Ratio

Combined
Score

PI3K-Akt signaling pathway
Focal adhesion
Cytokine-cytokine receptor
interaction
Regulation of lipolysis in
adipocytes
Hypertrophic cardiomyopathy
(HCM)
MAPK signaling pathway
Cell adhesion molecules
(CAMs)
Regulation of actin
cytoskeleton
TNF signaling pathway
Insulin resistance
PPAR signaling pathway
Estrogen signaling pathway
Osteoclast differentiation
TGF-beta signaling pathway
Insulin signaling pathway
Glycolysis / Gluconeogenesis
Adipocytokine signaling
pathway
Type II diabetes mellitus
Phospholipase D signaling
pathway
Inflammatory mediator
regulation of TRP channels
Drug metabolism
Pyruvate metabolism
Fatty acid biosynthesis
p53 signaling pathway
Thermogenesis
FoxO signaling pathway
Th17 cell differentiation

1.7E-10
3.3E-09

5.1E-08
5.0E-07

3.327
4.033

74.90
78.73

1.5E-07

9.1E-06

3.078

48.38

7.8E-06

3.4E-04

5.733

67.41

7.2E-05

2.4E-03

4.106

39.16

1.5E-04

3.4E-03

2.402

21.22

9.0E-04

1.5E-02

2.644

18.53

3.4E-03

4.3E-02

2.219

12.61

7.4E-03
7.4E-03
1.7E-02
2.4E-02
4.7E-02
6.5E-02
6.9E-02
1.6E-01

6.6E-02
6.8E-02
1.2E-01
1.6E-01
2.7E-01
3.6E-01
3.6E-01
6.0E-01

2.627
2.627
2.644
2.156
2.006
2.117
1.848
1.917

12.87
12.87
10.81
8.00
6.13
5.80
4.93
3.56

1.8E-01

6.5E-01

1.809

3.10

1.9E-01

6.5E-01

2.006

3.36

1.8E-01

6.6E-01

1.508

2.55

2.0E-01

7.0E-01

1.517

2.40

2.8E-01
3.3E-01
3.6E-01
3.8E-01
4.3E-01
5.9E-01
6.2E-01

8.6E-01
9.4E-01
9.6E-01
9.9E-01
1.0E+00
1.0E+00
1.0E+00

1.408
1.690
2.293
1.356
1.112
0.973
0.944

1.78
1.86
2.36
1.31
0.94
0.51
0.45
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Table 6.1 Continued from Previous Page.
Name
Signaling pathways regulating
pluripotency of stem cells
Citrate cycle (TCA cycle)

P-value

Adjusted
P-value

Odds
Ratio

Combined
Score

6.2E-01

1.0E+00

0.937

0.45

6.4E-01

1.0E+00

1.003

0.45

PI3K-AKT signaling affects many pathways involved in energy homeostasis, adipogenesis and metabolism, including glycolysis, gluconeogenesis, fatty acid oxidation and
cell cycle progression (Figure 6.8).

Figure 6.8: PI3K-AKT Signaling Pathway.

Further, I validated transcription factors in the PI3K-AKT pathway by western blot.
pFOXO1/3 was significantly increased in activin DKO in undifferentiated and differentiated MEFs suggesting that this transcription factor might play important roles at both
stages (undifferentiated and differentiated) (Figure 6.9 ). No change in the protein level
was observed for total FOXO1, pMTOR and pERK1/2. FOXO1/FOXO3 are required for
proliferation. Phosphorylated FOXO1/FOXO3 are excluded from nucleus and restrained in
the cytoplasm, thereby inhibiting proliferation. This phenotype is consistent with in vivo
data that activin deficiency in mice leads to arrested development of adipose tissue and
display markedly reduced adiposity (data not shown, Namwanje and Irudayam et al. in
preparation).
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Figure 6.9: Validation of Key Transcription Factors in Activin DKO and
WT MEFs. Western blot analysis showing of changes in the phosphorylation
of FOXO1/3 protein in differentiated and undifferentiated MEFs, total
FOXO1, pMTOR, PERK1/2 and GAPDH in activin DKO MEFs relative to
WT MEFs

6.3

Discussion

6.3.1

Early Stage of Browning in Activin DKO Adipocytes Is Intrinsic and Cell
Autonomous Due to Complete Loss of Activin A and Activin B

Activin signaling is a key pathways that regulates the expression of genes involved in
preadipocyte proliferation and subsequent differentiation into mature adipocytes for the
maintenance of adipose tissue mass (Zaragosi et al., 2010). Total loss of activin A and activin
B promotes differentiation of MEFs into adipocytes with brown-like characteristics as early
as day 3 (early stage differentiation) including abundant mitochondria with increased ETC
complex protein directly correlating with enhanced mitochondrial biogenesis and abundant
respiratory chain proteins. The expression of UCP1, PGC-1α and ETC complex proteins
suggest that the mitochondria of activin DKO cells are well equipped to meet a higher energy
demand than WT cells. In particular, the mitochondrial enrichment through upregulation
ETC complex proteins point out with no ambiguity that these effects are uniquely connected
to cell autonomous total loss of activin A and activin B. Total loss of activins A and activin
B significantly induced the expression of brown-like markers in differentiated MEFs. It
is important to note that the up regulation of browning markers is consistent with in
vivo data that the combined deficiency of activin A and activin B induced multiloculated
beige/brown-like cells in visceral WAT. SMAD2/3 are known downstream transcriptional
mediators of activin signaling, and whole transcriptome analysis revealed that in addition
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to SMAD2/3, FOXO1/FOXO3 of the PI3K-AKT pathway and PPARγ may also be key
transcriptional regulators of activin signaling during adipogenesis. In conclusion, whole
transcriptome analysis opens the way for the analysis of crosstalk between several signaling
pathways and associated downstream events for the regulation of genome organization and
WAT gene expression. These data are consistent with important roles for activins, SMAD2/3,
activin and crosstalk with additional metabolic signaling pathways including PI3K-AKT, in
the control of adipocyte proliferation and differentiation including adipocyte fate decisions.
Dysregulation of these processes has provided insight into mechanisms by which beneficial
metabolic effects, such as browning of WAT or protection from diet-induced obesity might
be achieved.
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Chapter 7
Conclusion and Significance

7.1

Conclusion

Activin A and activin B are TGF-β family members that play prominent roles in WAT. We
have shown that reduced activin signaling results in reduced adiposity and the appearance
of brown like cells in WAT in vivo, however the downstream molecular mechanism that
contribute to this phenotype remained unknown. The overall aim of this dissertation
was to investigate the role of activin/ SMAD2 and SMAD3 signaling on adipose tissue
function and the molecular mechanism(s) by which activin signaling regulates adipocyte
differentiation and cell fate using cellular approaches and mouse models. To examine the
cell autonomous roles of activin on cell proliferation, differentiation, and cell fate and the
contributions of downstream transcriptional transducers SMAD2/3 to these processes. This
study gave an additional insight into understanding the roles of activin/SMADs in the
regulation of adiposity.
The first aim of my dissertation included mouse model studies. Using these models,
we have demonstrated the roles of SMAD2 and SMAD3 on adipose tissue development
and function. We have shown that SMAD2 and SMAD3 proteins exhibit different temporal
expression during adipose tissue development confirmed in both visceral and subcutaneous
WAT. Adipose selective deletion of Smad2 had no role on adipose tissue development while
adipose-selective deletion of Smad3 partially protected the male mice from DIO. Smad3
deletion in male mice resulted in reduced adiposity in subcutaneous WAT as demonstrated
by smaller body weight, smaller depot and adipocyte sizes and by molecular markers in
subcutaneous fat depot. Furthermore, these findings support our hypothesis that SMAD3
functions in a depot-selective manner for the development of adipose tissue (Chapter 4).
The second aim of my dissertation included in vivo studies utilizing a combination of
the mouse model above. We demonstrated that the deletion of Smad2/3 in adipose tissues has
different outcomes in males and females with predominant effects of genotype and diet in
females. Smad2/3cKO mice demonstrated a sex-selective effect on weight gain. Smad2/3cKO
male mice showed no differences in body weight relative to controls, while female mice
gained less weight relative to control littermates on HFD, indicating a sex-influenced role
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for Smad2/3 on adiposity under HFD conditions with less visceral and subcutaneous fat
mass relative to controls. Hence female but not male mice are protected from diet induced
obesity. This is also consistent with the higher metabolic rates observed in Smad2/3cKO mice
and changes in the levels of key lipogenic and lipolytic genes. Considering all data, SMAD2
and SMAD3 not have redundant roles in adipose tissue development or function. SMAD2
and SMAD3 have acquired partial non-redundant functions in adipose tissue development
and function as loss of SMAD3 alone protected a subset of mice from DIO in male while loss
of both Smad2/3 protected a different subset from DIO corresponding to significant changes
in the expression of genes regulating metabolic responses (females only). Considering the
differences in the phenotypes observed in Smad3cKO alone (males only) and Smad2/3cKO
(females only), we speculate that the different responses of males and females are likely due
to the effect of sex-specific hormonal signaling. The combined phenotype is different from
either of the single Smad mutants. This study highlights the importance of biological sex as
an important modifier of the phenotype observed with the combined deletion of Smad2/3
(Chapter 5).
The third aim of my dissertation included in vitro studies utilizing MEFs isolated
from wild type mice and activin A and B deficient double mutant mice. We confirmed the
cell autonomous role of activin on preadipocyte proliferation and confirmed that activin A
promotes preadipocyte proliferation. We have observed that the combined global knockout
of activin A (Inhba) and activin B (Inhbb), enhanced adipocyte differentiation from MEFs,
including the appearance of UCP1 positive brown-like cells with increased numbers of
mitochondria. Additionally, gene expression profiling, immunofluorescence and western
blotting were all consistent with a brown-like cellular phenotype. Collectively, our data
indicated that activin signaling may regulate cell proliferation, differentiation, and energy
homeostasis (Chapter 6).
Collectively, the results obtained from this study provide additional insight to expand
our knowledge about the direct effects of SMAD2/3 on adipocyte development and function
and the molecular pathway(s) that regulate adiposity and energy metabolism in response
to activin signaling. This study has identified the phenotypic differences between global
knockout of Smad3 and adipose-selective knockout of Smad3 (including no report of sexual
dimorphism). Also, these findings are informative in determining the importance of
activin/SMAD2/3 signaling in the context of obesity and may prove an effective and safe
target for therapies aimed at treating or preventing obesity.

7.2

Future Directions

This body of work has explored the roles of Smad2, Smad3 and Smad2/3 during mid to-late
stages of adipogenesis. Out of these findings, there are several unanswered questions that
can be addressed, such as the potential roles of Smad2 and Smad3 in early adipogenesis
using an early preadipocyte-specific Cre (Pdgrfα Cre). Additionally, determining if there
is redundancy of Smad2 and Smad3 during early adipogenous is highly important given
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the fact that activin (upstream of SMAD2/3) has a clearly established role in this context.
It is important to acknowledge the potential limitation of this study with the use the
Adiponectin-Cre mouse. With this Cre, early stage adipose-selective gene inactivation occurs
in the early to middle to late stages of adipogenesis, starting at the preadipocyte stage
and continuing in their descendants. It is plausible that SMAD-mediated events occurring
at earlier stages would not be impacted. Thus, to fully understand the role of SMADmediated activin signaling and underlying molecular mechanisms that occur during earlier
stages, additional studies are needed using alternative strategies including inducible models
that confer spatiotemporal control. This study will further address the activin/SMADs
relationship in regulating adipogenesis. The proposed study may also answer if activin
regulates preadipocyte proliferation and adipogenesis by phosphorylating SMAD2, SMAD3
or both before adipogenesis begins.
It is very important to investigate the molecular mechanism(s) by which SMAD2/3
modulate sex-selective phenotypes. There are only a few instances, to our knowledge,
which show that SMAD3 has a more pronounced effect in males, one for the progression
of gonadal tumorigenesis (Q. Li, Graff, et al., 2007), the other, androgen-promoted growth
inhibition in the prostate, androgen restricted to males (Hayes et al., 2001). Interestingly,
Growth Differentiation Factor 3, another ligand within the TGF-β family (that can use the
same set of type I receptors as activins), has also shown evidence of sexual dimorphism, with
a more pronounced protection from diet-induced obesity in global knockout females (J. J.
Shen et al., 2009). Thus, sexual dimorphism within the TGF-β family is established. While
the mechanisms underlying these phenomena are likely complex, thought to involve both
environmental/hormonal and genetic influences (Ober, Loisel, and Gilad, 2008), additional
studies are required to better understand these effects in the current model.
Another long-term goal is to enhance our understanding of the developmental
origins of “brite adipocy-tes”. The future study may include a novel methods to characterize
and manipulate primary preadipocytes to study trans-differentiation and to look at the
downstream transcription factors including Forkhead box (FOX) that play important roles
in cell cycle regulation. The role of FOX is unknown in the context of activin signaling.
FOXO1, an inhibitor of proliferation process, activates the promoter of p21, a negative cell
cycle regulator that causes G1 arrest before entering mitotic clonal expansion. SMAD2
and SMAD3 form an activating complex with FOXO1 at the p21 promoter (L. Wang et al.,
2018; Seoane et al., 2004). It is plausible that the growth arrest of activin-deficient mice
could be associated with the activation of FOXO1. Additionally, FOXC2 participates in
white to brown adipocyte conversion by forming a transcriptional complex with SMAD3
and SMAD4 at the plasminiogen activator inhibitor-1 (PAI-1) promoter. This interaction is
antagonized by FOXO1 through competition for common DNA binding sites (Fujita et al.,
2006). Therefore, investigation of direct roles for FOX/SMADs interactions in transcriptional
regulation in context of activin signaling and roles during adipogenesis will likely provide
additional mechanistic insight.
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This body of work has discovered an additional insight into the direct effects of
Smad2/3 on adipocyte function and the mechanism(s) that regulates adiposity and energy
metabolism. The results of this study enhanced our current knowledge and complexity
about the adipose-selective effects of Smad2 and Smad3 on adipocyte function and redundancy of both proteins in terms of regulating energy homeostasis and obesity; thereby
identifying possible therapeutic targets for the treatment of obesity. Therefore, such studies
were essential to investigate the overall impact of SMAD2 and SMAD3 on the progression
of obesity and possibly a potential platform to design effective anti-obesity treatments.
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